<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients - Hahn, D - 2017 | Cochrane Library</title> <meta content="Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients - Hahn, D - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011690.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients - Hahn, D - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011690.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011690.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients" name="citation_title"/> <meta content="Deirdre Hahn" name="citation_author"/> <meta content="The Children's Hospital at Westmead" name="citation_author_institution"/> <meta content="Deirdre.hahn@health.nsw.gov.au" name="citation_author_email"/> <meta content="Christopher I Esezobor" name="citation_author"/> <meta content="College of Medicine, University of Lagos" name="citation_author_institution"/> <meta content="Noha Elserafy" name="citation_author"/> <meta content="The Children's Hospital at Westmead" name="citation_author_institution"/> <meta content="Angela C Webster" name="citation_author"/> <meta content="Elisabeth M Hodson" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD011690.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/01/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011690.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011690.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011690.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anemia [blood, *drug therapy]; Epoetin Alfa [*administration &amp; dosage]; Erythropoietin [*administration &amp; dosage]; Hematinics [*administration &amp; dosage]; Hemoglobin A; Injections, Intravenous; Randomized Controlled Trials as Topic; Recombinant Proteins [administration &amp; dosage]; *Renal Dialysis; Renal Insufficiency, Chronic [*blood]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011690.pub2&amp;doi=10.1002/14651858.CD011690.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="i9CklieH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011690\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011690\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011690.pub2",title:"Short\\u2010acting erythropoiesis\\u2010stimulating agents for anaemia in predialysis patients",firstPublishedDate:"Jan 9, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011690.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011690.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011690.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011690.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011690.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011690.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011690.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011690.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011690.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011690.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2387 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011690.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/appendices#CD011690-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/table_n/CD011690StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/table_n/CD011690StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/information#CD011690-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Deirdre Hahn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/information#CD011690-cr-0003">Christopher I Esezobor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/information#CD011690-cr-0004">Noha Elserafy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/information#CD011690-cr-0005">Angela C Webster</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011690.pub2/information#CD011690-cr-0006">Elisabeth M Hodson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/information/en#CD011690-sec-0097">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 January 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011690.pub2">https://doi.org/10.1002/14651858.CD011690.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011690-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011690-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011690-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011690-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011690-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011690-abs-0001" lang="en"> <section id="CD011690-sec-0001"> <h3 class="title" id="CD011690-sec-0001">Background</h3> <p>The benefits of erythropoiesis‐stimulating agents (ESA) for chronic kidney disease (CKD) patients have been previously demonstrated. However, the efficacy and safety of short‐acting epoetins administered at larger doses and reduced frequency as well as of new epoetins and biosimilars remains uncertain. </p> </section> <section id="CD011690-sec-0002"> <h3 class="title" id="CD011690-sec-0002">Objectives</h3> <p>This review aimed to evaluate the benefits and harms of different routes, frequencies and doses of epoetins (epoetin alpha, epoetin beta and other short‐acting epoetins) for anaemia in adults and children with CKD not receiving dialysis. </p> </section> <section id="CD011690-sec-0003"> <h3 class="title" id="CD011690-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Specialised Register to 12 September 2016 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference proceedings; and searching the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD011690-sec-0004"> <h3 class="title" id="CD011690-sec-0004">Selection criteria</h3> <p>We included randomised control trials (RCTs) comparing different frequencies, routes, doses and types of short‐acting ESAs in CKD patients. </p> </section> <section id="CD011690-sec-0005"> <h3 class="title" id="CD011690-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed study eligibility and four authors assessed risk of bias and extracted data. Results were expressed as risk ratio (RR) or risk differences (RD) with 95% confidence intervals (CI) for dichotomous outcomes. For continuous outcomes the mean difference (MD) with 95% confidence intervals (CI) was used. Statistical analyses were performed using the random‐effects model. </p> </section> <section id="CD011690-sec-0006"> <h3 class="title" id="CD011690-sec-0006">Main results</h3> <p>We identified 14 RCTs (2616 participants); nine studies were multi‐centre and two studies involved children. The risk of bias was high in most studies; only three studies demonstrated adequate random sequence generation and only two studies were at low risk of bias for allocation concealment. Blinding of participants and personnel was at low risk of bias in one study. Blinding of outcome assessment was judged at low risk in 13 studies as the outcome measures were reported as laboratory results and therefore unlikely to be influenced by blinding. Attrition bias was at low risk of bias in eight studies while selective reporting was at low risk in six included studies. </p> <p>Four interventions were compared: epoetin alpha or beta at different frequencies using the same total dose (six studies); epoetin alpha at the same frequency and different total doses (two studies); epoetin alpha administered intravenously versus subcutaneous administration (one study); epoetin alpha or beta versus other epoetins or biosimilars (five studies). One study compared both different frequencies of epoetin alpha at the same total dose and at the same frequency using different total doses. </p> <p>Data from only 7/14 studies could be included in our meta‐analyses. There were no significant differences in final haemoglobin (Hb) levels when dosing every two weeks was compared with weekly dosing (4 studies, 785 participants: MD ‐0.20 g/dL, 95% CI ‐0.33 to ‐0.07), when four weekly dosing was compared with two weekly dosing (three studies, 671 participants: MD ‐0.16 g/dL, 95% CI ‐0.43 to 0.10) or when different total doses were administered at the same frequency (four weekly administration: one study, 144 participants: MD 0.17 g/dL 95% CI ‐0.19 to 0.53). </p> <p>Five studies evaluated different interventions. One study compared epoetin theta with epoetin alpha and found no significant differences in Hb levels (288 participants: MD ‐0.02 g/dL, 95% CI ‐0.25 to 0.21). One study found significantly higher pain scores with subcutaneous epoetin alpha compared with epoetin beta. Two studies (165 participants) compared epoetin delta with epoetin alpha, with no results available since the pharmaceutical company withdrew epoetin delta for commercial reasons. The fifth study comparing the biosimilar HX575 with epoetin alpha was stopped after patients receiving HX575 subcutaneously developed anti‐epoetin antibodies and no results were available. </p> <p>Adverse events were poorly reported in all studies and did not differ significantly within comparisons. Mortality was only detailed adequately in four studies and only one study included quality of life data. </p> </section> <section id="CD011690-sec-0007"> <h3 class="title" id="CD011690-sec-0007">Authors' conclusions</h3> <p>Epoetin alpha given at higher doses for extended intervals (two or four weekly) is non‐inferior to more frequent dosing intervals in maintaining final Hb levels with no significant differences in adverse effects in non‐dialysed CKD patients. However the data are of low methodological quality so that differences in efficacy and safety cannot be excluded. Further large, well designed, RCTs with patient‐centred outcomes are required to assess the safety and efficacy of large doses of the shorter acting ESAs, including biosimilars of epoetin alpha, administered less frequently compared with more frequent administration of smaller doses in children and adults with CKD not on dialysis. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011690-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011690-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011690-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011690-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011690-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011690-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011690-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011690-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011690-abs-0003" lang="en"> <h3>Short‐acting erythropoiesis agents in chronic kidney disease patients not requiring dialysis </h3> <p><b>What is the issue?</b> </p> <p>Anaemia due to reduced production by the kidneys of erythropoietin (a hormone which increases red cell production) is a major cause of tiredness and other problems experienced by people with chronic kidney disease requiring or not requiring dialysis. </p> <p>Manufactured erythropoietins (epoetins) improve anaemia and are often prescribed for people with chronic kidney disease. Several different manufactured epoetins are now available. </p> <p><b>What did we do?</b> </p> <p>We searched the Cochrane Kidney and Transplant Specialised Register to 12 September 2016 through contact with the Information Specialist using search terms relevant to this review. We included randomised control trials (RCTs) comparing different frequencies, routes, doses and types of short‐acting ESAs in patients with chronic kidney disease. </p> <p><b>What did we find?</b> </p> <p>We examined the evidence from 14 studies with 2616 participants with CKD not receiving dialysis published before 12 September 2016 to determine whether differences in improvement in anaemia and in side effects existed between different short‐acting epoetins or between the same epoetins given at different frequencies. We did not find any studies using different frequencies of epoetins in children. </p> <p>We found that the traditionally shorter acting epoetins given less often (two weekly to every four weeks) resulted in similar correction of anaemia compared with administration every week or every two weeks; there were no differences in side effects between the different comparisons. One study comparing subcutaneous administration of a newly manufactured HX575 epoetin alpha compared with epoetin alpha was discontinued after two patients developed anti‐erythropoietin antibodies. However more studies are required as most studies were small and poorly designed, which limits their application to the care of patients. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011690-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011690-sec-0088">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011690-sec-0125">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011690-sec-0088"></div> <h3 class="title" id="CD011690-sec-0089">Implications for practice</h3> <section id="CD011690-sec-0089"> <p>A previous review identified that epoetin alpha was effective compared with placebo or no treatment in raising Hb levels without a significant reduction in GFR in patients with CKD not on dialysis (<a href="./references#CD011690-bbs2-0040" title="CodyJD , HodsonEM . Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. Cochrane Database of Systematic Reviews2016, Issue 1. [DOI: 10.1002/14651858.CD003266.pub3] ">Cody 2016</a>). Our review extends these observations to show that epoetin alpha given at higher doses for extended intervals is non‐inferior to more frequent dosing intervals. The benefits offered by the extended dosing intervals include convenience for the patients and healthcare providers and may also result in cost efficiency. This may be of benefit in countries with more limited resources and access to longer acting more costly ESAs. However the data are of low quality so that differences in efficacy and adverse effects cannot be completely excluded. We did not identify any studies which evaluated different frequencies of epoetin beta. In a single study, epoetin theta did not differ significantly from epoetin beta in haematological outcomes or adverse effects. </p> <p>We only identified one study in predialysis patients comparing a biosimilar preparation of epoetin alpha (HX575 epoetin alpha, Binocrit<sup>®</sup>) in non‐dialysis patients and this study was terminated because of the development of pure red cell aplasia with neutralising antibodies (<a href="./references#CD011690-bbs2-0006" title="Haag‐WeberM , EckardtKU , HorlWH , RogerSD , VetterA , RothK . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin‐alpha (HX575) in non‐dialysis patients with renal anemia: a multi‐center, randomized, double‐blind study. Clinical Nephrology2012;77(1):8‐17. [MEDLINE: 22185963] ">Haag‐Weber 2012</a>). HX575 epoetin alpha and a second biosimilar of epoetin alpha (epoetin zeta, Retacrit<sup>®</sup>) received marketing authorization throughout the European Union in 2007; HX575 epoetin alpha is limited to intravenous use. Because the safety record of these compounds is limited compared with epoetin alpha and epoetin beta, the ERBP Work Group recommends stringent pharmacovigilance for biosimilars of epoetin alpha (<a href="./references#CD011690-bbs2-0043" title="LocatelliF , CovicA , EckardtKU , WiecekA , Vanholder R. ERA‐EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation2009;24(2):348‐54. [MEDLINE: 19037082] ">ERBP 2009</a>). Two clinical studies evaluating the biosimilar HX575 epoetin alpha in the USA have been completed (NCT01693029a, NCT01576341a) but the results are not yet available. Of these one (NCT01576341a) evaluated subcutaneous administration of HX575 epoetin alpha in predialysis patients in a single arm study aiming to determine efficacy, adverse effects and the incidence of anti‐epoetin antibodies. The uptake in the nephrology community of the biosimilar ESAs will ultimately depend on the balance between cost savings and residual concerns regarding safety (<a href="./references#CD011690-bbs2-0059" title="MikhailA , FaroukM . Epoetin biosimilars in Europe: five years on. Advances in Therapy2013;30(1):28‐40. [MEDLINE: 23242745] ">Mikhail 2013</a>; <a href="./references#CD011690-bbs2-0068" title="SchellekensH . Biosimilar therapeutics ‐ what do we need to consider?. NDT Plus2009;2(Suppl 1):i27‐i36. [DOI: 10.1093/ndtplus/sfn177] ">Schellekens 2009</a>). </p> </section> <h3 class="title" id="CD011690-sec-0090">Implications for research</h3> <section id="CD011690-sec-0090"> <p>As noted in earlier ESA reviews (<a href="./references#CD011690-bbs2-0048" title="HahnD , CodyJD , HodsonEM . Frequency of administration of erythropoiesis‐stimulating agents for the anaemia of end‐stage kidney disease in dialysis patients. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD003895.pub3] ">Hahn 2014</a>; <a href="./references#CD011690-bbs2-0073" title="StrippoliGF , NavaneethanSD , CraigJC , PalmerSC . Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD003967.pub2] ">Strippoli 2006</a>) the reporting of treatment effects of ESAs on potentially important patient outcomes is heterogeneous and poor, thereby limiting a good understanding of how ESA therapy affects the way patients feel and function. Currently decisions regarding different agents in clinical practice are dictated by physician and patient preference, drug cost and availability since we have inconclusive evidence of the effects of different short‐acting ESAs or of different frequencies of ESA administration on survival and quality of life. Data regarding effectiveness and safety when treating children with ESAs remains limited. </p> <p>Therefore additional large, well designed, randomised studies are required in the following areas to compare larger doses of the shorter acting ESAs including new biosimilars of epoetin alpha administered less frequently with more frequent dosing in both children and adults with CKD not on dialysis. These studies should include patient‐centred outcomes including all‐cause mortality, cardiovascular mortality and morbidity, and quality of life assessment. Estimates of patient and carer satisfaction related to different frequencies of administration should be included. Studies of cost‐effectiveness of different frequencies of administration should also be undertaken. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011690-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011690-sec-0022"></div> <div class="table" id="CD011690-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Epoetin alpha every 2 weeks versus to weekly for anaemia in CKD patients not receiving dialysis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Epoetin alpha every 2 weeks versus to weekly for anaemia in CKD patients not receiving dialysis </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> anaemia in predialysis patients<br/> <b>Intervention:</b> epoetin alpha every 2 weeks<br/> <b>Comparison:</b> weekly </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with weekly</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Epoetin alpha every 2 weeks</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in Hb level</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Hb level was 0 g/dL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Hb level in the intervention group was 0.19 g/dL lower (0.32 g/dL lower to 0.06 g/dL lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>798 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>downgraded for study limitations and indirectness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Number reaching target Hb</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.96<br/> (0.93 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>798 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations and indirectness</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>960 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>922 per 1000<br/> (893 to 951) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>947 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>910 per 1000<br/> (881 to 938) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Number of deaths</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.89<br/> (0.38 to 2.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>838 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations and imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/> (10 to 57) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (9 to 46) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: RBC transfusions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.56<br/> (0.71 to 3.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>580 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for imprecision and study limitations</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000<br/> (23 to 114) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/> (26 to 128) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: hypertension</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.85<br/> (0.55 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>838 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000<br/> (55 to 132) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/> (52 to 126) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: thrombovascular events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.41<br/> (0.67 to 3.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>838 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations and imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/> (18 to 83) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/> (18 to 80) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; <b>Hb:</b> haemoglobin; <b>RBC:</b> red blood cells </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> allocation concealment unclear in 3 of 4 studies </p> <p><sup>2</sup> surrogate outcome </p> <p><sup>3</sup> few studies with low numbers and wide confidence </p> <p><sup>4</sup> allocation concealment unclear in 2 of 3 studies </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011690-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Epoetin alfa every four weeks versus with every two weeks in CKD patients not receiving dialysis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Epoetin alfa every four weeks versus with every two weeks in CKD patients not receiving dialysis </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> anaemia in predialysis patients<br/> <b>Intervention:</b> epoetin alpha every 4 weeks<br/> <b>Comparison:</b> every 2 weeks </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with every 2 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Epoetin alpha every 4 weeks</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in Hb level</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Hb level was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Hb level in the intervention group was 0.15g/dL lower (0.41 g/dL lower to 0.1g/dL more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>671 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>downgraded for study limitations, heterogeneity and indirectness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Number reaching target Hb</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.95<br/> (0.84 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>687 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations, heterogeneity and indirectness</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>916 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>870 per 1000<br/> (769 to 980) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>895 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>850 per 1000<br/> (752 to 957) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Number of deaths</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.95<br/> (0.33 to 2.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>724 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations, imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (7 to 62) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (9 to 72) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: RBC transfusions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.26<br/> (0.53 to 2.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>470 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations, imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/> (20 to 114) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000<br/> (18 to 103) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: hypertension</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.02<br/> (0.62 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>724 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000<br/> (44 to 119) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000<br/> (38 to 104) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: arteriovenous complications</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.02<br/> (0.39 to 2.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>724 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations, imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (10 to 68) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/> (9 to 62) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; <b>Hb:</b> haemoglobin; <b>RBC:</b> red blood cells </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> two of the three studies had unclear allocation concealment </p> <p><sup>2</sup> surrogate outcome </p> <p><sup>3</sup> unexplained heterogeneity </p> <p><sup>4</sup> small numbers with wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011690-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Epoetin theta versus epoetin beta in CKD patients not receiving dialysis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Epoetin theta versus epoetin beta in CKD patients not receiving dialysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> anaemia in predialysis patients<br/> <b>Intervention:</b> epoetin theta<br/> <b>Comparison:</b> epoetin beta </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with epoetin beta</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Epoetin theta</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final Hb</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final Hb was 0 g/dL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final Hb in the intervention group was 0.02 g/dL lower (0.25 g/dL lower to 0.21 g/dL higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>downgraded for indirectness ‐ surrogate outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean weekly epoetin dose</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean weekly epoetin dose was 0 units/week</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean weekly epoetin dose in the intervention group was 0.4 units per week higher (5.68 units per week lower 6.48 units/week higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>downgraded for indirectness ‐ surrogate outcomes and imprecision</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Deaths</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 2.46<br/> (0.29 to 20.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>288 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (3 to 219) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (3 to 218) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: hypertension</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.35<br/> (0.11 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>288 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (8 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (8 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: RBC transfusions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.48<br/> (0.06 to 36.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>288 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>downgraded for imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: discontinuation of therapy</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.77<br/> (0.68 to 4.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>288 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000<br/> (36 to 244) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000<br/> (36 to 244) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; <b>RBC:</b> red blood cells </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Surrogate outcome, not a patient‐centred outcome </p> <p><sup>2</sup> Small numbers, wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011690-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011690-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011690-sec-0103">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011690-sec-0023"></div> <section id="CD011690-sec-0024"> <h3 class="title" id="CD011690-sec-0024">Description of the condition</h3> <p>Anaemia is defined as haemoglobin (Hb) levels &lt; 12.0 g/dL and 13.0 g/dL in adult females and males respectively based on the World Health Organization's definition of anaemia (<a href="./references#CD011690-bbs2-0052" title="KDIGO . KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International ‐ Supplement2012;2(4):279‐335. ">KDIGO 2012</a>; <a href="./references#CD011690-bbs2-0075" title="World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. World Health Organization. 2011. www.who.int/vmnis/indicators/haemoglobin/en/ (accessed 15 December 2016). [WHO/NMH/NHD/MNM/11.1] ">WHO 2011</a>). Anaemia is diagnosed in children with chronic kidney disease (CKD) if Hb concentration is &lt; 11.0 g/dL in children aged from six months to five years, &lt; 11.5 g/dL in children aged five to 12 years, and &lt; 12.0 g/dL in children from 12 to 15 years of age according to the Kidney Disease Improving Global Outcomes guidelines (<a href="./references#CD011690-bbs2-0052" title="KDIGO . KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International ‐ Supplement2012;2(4):279‐335. ">KDIGO 2012</a>). Anaemia is a known complication of CKD (<a href="./references#CD011690-bbs2-0041" title="DmitrievaO , deLusignanS , MacdougallIC , GallagherH , TomsonC , HarrisK , et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrology2013;14:24. [MEDLINE: 23351270] ">Dmtrieva 2013</a>) which develops as kidney function declines; prevalence increases as glomerular filtration rate (GFR) falls. CKD stage 3 to 5 is a predictor variable of decline in Hb (<a href="./references#CD011690-bbs2-0041" title="DmitrievaO , deLusignanS , MacdougallIC , GallagherH , TomsonC , HarrisK , et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrology2013;14:24. [MEDLINE: 23351270] ">Dmtrieva 2013</a>). </p> <p>Anaemia prevalence ranges from 25% to 70% (<a href="./references#CD011690-bbs2-0051" title="HsuCY , McCullochCE , CurhanGC . Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. Journal of the American Society of Nephrology2002;13(2):504‐10. [MEDLINE: 11805181] ">Hsu 2002</a>; <a href="./references#CD011690-bbs2-0053" title="KochKM , FreiU . Treatment of renal anemia, 1960‐1990. Advances in Nephrology From the Necker Hospital1991;20:19‐30. [MEDLINE: 2063711] ">Koch 1991</a>), and most people with CKD stage 5 (GFR &lt; 15 mL/min/1.73 m<sup>2</sup>) are anaemic (<a href="./references#CD011690-bbs2-0034" title="AstorBC , MuntnerP , LevinA , EustaceJA , CoreshJ . Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988‐1994). Archives of Internal Medicine2002;162(2):1401‐8. [MEDLINE: 12076240] ">Astor 2002</a>). Anaemia related to CKD results in significant morbidity, mortality and increased cardiovascular events, with symptoms including lack of energy, breathlessness, dizziness, angina, poor appetite and decreased exercise tolerance (<a href="./references#CD011690-bbs2-0037" title="Anonymous . Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ1990;300(6724):573‐8. [MEDLINE: 2108751] ">Canadian EPO 1990</a>; <a href="./references#CD011690-bbs2-0056" title="LundinAP . Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy. Seminars in Nephrology1989;9(1 Suppl 1):22‐9. [MEDLINE: 2648517] ">Lundin 1989</a>). </p> <p>The primary cause of anaemia in CKD is decreased production of the naturally‐occurring hormone, erythropoietin (EPO) in the kidney. Anaemia may be exacerbated by concurrent iron deficiency anaemia (<a href="./references#CD011690-bbs2-0052" title="KDIGO . KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International ‐ Supplement2012;2(4):279‐335. ">KDIGO 2012</a>). </p> <p>Prior to the availability of recombinant human EPO (rHuEPO), anaemia was managed with blood transfusions together with iron and folate supplements. Cloning of the human gene for EPO was achieved in 1983 (<a href="./references#CD011690-bbs2-0054" title="LinFK , SuggsS , LinCH , BrowneJK , SmallingR , EgrieJC , et al. Cloning and expression of the human erythropoietin gene. Proceedings of the National Academy of Sciences of the United States of America1985;82(22):7580‐4. [MEDLINE: 3865178] ">Lin 1985</a>) and production of rHuEPO followed. The efficacy of erythropoiesis‐stimulating agents (ESA) treatment in dialysis patients was demonstrated in 1986 (<a href="./references#CD011690-bbs2-0076" title="WinearlsCG , OliverDO , PippardMJ , ReidC , DowningMR , CotesPM . Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet1986;2(8157):1175‐8. [MEDLINE: 2877323] ">Winearls 1986</a>) and several randomised controlled trials (RCTs) have documented a beneficial effect of ESA treatment in correcting the anaemia of CKD in non‐dialysis patients (<a href="./references#CD011690-bbs2-0039" title="CodyJD , DalyC , CampbellMK , KhanI , RabindranathKS , ValeL , et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre‐dialysis patients. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD003266.pub2] ">Cody 2005</a>; <a href="./references#CD011690-bbs2-0072" title="StoneWJ , GraberSE , KrantzSB , DessyprisEN , O'NeilVL , OlsenNJ , et al. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo‐controlled trial. American Journal of the Medical Sciences1988;296(3):171‐9. [MEDLINE: 3177433] ">Stone 1988</a>). </p> <p>The increase in Hb levels following treatment with ESA leads to improved energy levels (<a href="./references#CD011690-bbs2-0077" title="WolcottDL , MarshJT , LaRueA , CarrC , NissensonAR . Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. American Journal of Kidney Diseases1989;14(6):478‐85. [MEDLINE: 2596475] ">Wolcott 1989</a>), improved cardiac performance and increased ejection fraction (<a href="./references#CD011690-bbs2-0065" title="PappasKD , GouvaCD , KatopodisKP , NikolopoulosPM , KorantzopoulosPG , MichalisLK , et al. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovascular Drugs &amp; Therapy2008;22(1):37‐44. [MEDLINE: 18095148] ">Pappas 2008</a>) with normalisation of cardiac output and reduced left ventricular mass (<a href="./references#CD011690-bbs2-0038" title="CannellaG , LaCannaG , SandriniM , GaggiottiM , NordioG , MovilliE , et al. Renormalization of high cardiac output and of left ventricular size following long‐term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clinical Nephrology1990;34(6):272‐8. [MEDLINE: 2073771] ">Cannella 1990</a>). The benefits of early treatment of anaemia with ESA in predialysis patients include increased exercise capacity, improved quality of life, improved cognitive function and a slower decline in kidney function (<a href="./references#CD011690-bbs2-0066" title="RitzE , EisenhachtA . Early epoetin treatment in patients with renal insufficiency. Nephrology Dialysis Transplantation2000;15 Suppl 3:40‐4. [MEDLINE: 11032357] ">Ritz 2000</a>; <a href="./references#CD011690-bbs2-0067" title="RothD , SmithRD , SchulmanG , SteinmanTI , HatchFE , RudnickMR , et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. American Journal of Kidney Diseases1994;24(5):777‐84. [MEDLINE: 7977319] ">Roth 1994</a>). </p> </section> <section id="CD011690-sec-0025"> <h3 class="title" id="CD011690-sec-0025">Description of the intervention</h3> <p>Administration of an ESA aims to replace endogenous EPO production, raise Hb levels and alleviate signs and symptoms of anaemia. Epoetin alpha has proven efficacy in treating anaemia in people with CKD (<a href="./references#CD011690-bbs2-0044" title="EschbachJW , EgrieJC , DowningMR , BrowneJK , AdamsonJW . Correction of the anemia of end‐stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New England Journal of Medicine1987;316(2):73‐8. [MEDLINE: 3537801] ">Eschbach 1987</a>). Epoetin alpha has a relatively short half‐life and typically is administered twice or thrice weekly (<a href="./references#CD011690-bbs2-0055" title="LocatelliF , DelVecchioL . Erythropoiesis‐stimulating agents in renal medicine. Oncologist2011;16 Suppl 3:19‐24. [MEDLINE: 21930831] ">Locatelli 2011</a>). More recently new longer acting ESAs, which can be administered less frequently than short‐acting ESAs, have been developed allowing administration of ESA every one to four weeks depending on the preparation used and the individual patient response. Darbepoetin was the first ESA with a prolonged half‐life to enter the market enabling administration once a week to four weekly (<a href="./references#CD011690-bbs2-0057" title="MacdougallIC , GraySJ , ElstonO , BreenC , JenkinsB , BrowneJ , et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Journal of American Society of Nephrology1999;10(11):2392‐5. [MEDLINE: 10541299] ">Macdougall 1999</a>). More recently, the use of the continuous EPO receptor activator (CERA), a pegylated epoetin, has extended dosing intervals to one dose every two to four weeks (<a href="./references#CD011690-bbs2-0058" title="MacdougallIC . CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis‐stimulating agent for the treatment of anemia. Current Hematology Reports2005;4(6):436‐40. [MEDLINE: 16232379] ">Macdougall 2005</a>). ESAs have to be administered intravenously or subcutaneously so the benefits of using ESAs in non‐dialysis CKD patients, who will generally receive subcutaneous injections in an outpatient setting, must be balanced against the inconvenience and/or discomfort of injections as well as potential harms of ESAs, which include hypertension, vascular access thrombosis and cardiovascular events. A significant concern in ESA therapy is the Hb target to be achieved. The CHOIR study reported a target Hb level of 13.5 g/dL compared with 11.3 g/dL was associated with increased mortality and cardiovascular risk and no considerable improvement in the quality of life. The study could not provide an explanation for poorer outcomes in patients with a higher target Hb (<a href="./references#CD011690-bbs2-0071" title="SinghAK , SzczechL , TangKL , BarnhartH , SappS , WolfsonM , et al. Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine2006;355(20):2085‐98. [MEDLINE: 17108343] ">Singh 2006</a>). Recommendations on when to commence ESA therapy are outlined in the KDIGO guidelines (<a href="./references#CD011690-bbs2-0052" title="KDIGO . KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International ‐ Supplement2012;2(4):279‐335. ">KDIGO 2012</a>). As the patents for epoetin alpha have expired, cheaper biosimilars of epoetin alpha have been developed. These biological products are highly similar though not identical to reference products and undergo a more limited appraisal before receiving marketing approval. As they are not generic versions of the reference products and could have differences particularly in adverse effects, these products should be submitted to rigorous assessment before marketing and to long term monitoring to ensure that adverse effects are recognised and attributed to the responsible biological preparation (<a href="./references#CD011690-bbs2-0059" title="MikhailA , FaroukM . Epoetin biosimilars in Europe: five years on. Advances in Therapy2013;30(1):28‐40. [MEDLINE: 23242745] ">Mikhail 2013</a>; <a href="./references#CD011690-bbs2-0068" title="SchellekensH . Biosimilar therapeutics ‐ what do we need to consider?. NDT Plus2009;2(Suppl 1):i27‐i36. [DOI: 10.1093/ndtplus/sfn177] ">Schellekens 2009</a>). </p> </section> <section id="CD011690-sec-0026"> <h3 class="title" id="CD011690-sec-0026">How the intervention might work</h3> <p>The primary cause of anaemia in CKD is the relative insufficiency of EPO which is mainly produced by peritubular fibroblasts in the kidney. EPO is part of a widespread system of hypoxia‐inducible gene expression mediated by hypoxia‐inducible transcription factors (HIFs).The factors associated with inadequate EPO production in progressive CKD remain unclear, though recent data indicate a deranged oxygen sensing, in addition to loss of EPO production, is involved (<a href="./references#CD011690-bbs2-0035" title="BernhardtWM , WiesenerMS , ScigallaP , ChouJ , SchmiederRE , GunzlerV , et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. Journal of the American Society of Nephrology2010;21(12):2151‐6. [MEDLINE: 21115615] ">Bernhardt 2010</a>). ESAs accelerate erythropoiesis, increase iron utilisation and raise Hb levels with clinical improvement in signs and symptoms of anaemia and avoidance of blood transfusions. ESA therapy aims to increase Hb levels slowly at a rate of 1 to 2 g/dL per month to correct anaemia. After correction of anaemia, dose adjustment may be necessary to maintain a stable Hb level. Anaemia is corrected slowly with ESA to avoid major side effects including hypertension and thrombotic events. ESA requirements are difficult to predict in individual patients, and may be increased in people with associated co‐morbidities including cardiovascular disease, diabetes, chronic inflammation and severe secondary hyperparathyroidism. ESA requirements are generally lower in patients not receiving dialysis. A major issue in ESA use relates to the Hb target to be achieved with increased cardiovascular risk noted with higher Hb targets (<a href="./references#CD011690-bbs2-0042" title="DruekeTB , LocatelliF , ClyneN , EckardtKU , MacdougallIC , TsakirisD , et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine2006;355(20):2071‐84. [MEDLINE: 17108342] ">Drueke 2006</a>; <a href="./references#CD011690-bbs2-0071" title="SinghAK , SzczechL , TangKL , BarnhartH , SappS , WolfsonM , et al. Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine2006;355(20):2085‐98. [MEDLINE: 17108343] ">Singh 2006</a>). Recent systematic reviews have suggested that aiming for Hb levels similar to those seen in healthy adults is associated with a significantly higher risk of mortality due to cardiovascular events, such as stroke and hypertension (<a href="./references#CD011690-bbs2-0061" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , TonelliM , GargAX , et al. Meta analysis: erythropoiesis stimulating agents in patients with chronic kidney disease. Annals of Internal Medicine2010;153(1):23‐33. [MEDLINE: 20439566] ">Palmer 2010</a>). The mechanisms for these treatment‐related harms are poorly understood though observational studies suggest treatment related toxicity secondary to impaired Hb responses and incremental erythropoietin dosing (<a href="./references#CD011690-bbs2-0074" title="SzczechLA , BarnhartHX , InrigJK , ReddanDN , SappS , CaliffRM , et al. Secondary analysis of the CHOIR trial epoetin‐alpha dose and achieved hemoglobin outcomes. Kidney international2008;74(6):791‐8. [MEDLINE: 18596733] ">Szczech 2008</a>). KDIGO guidelines (<a href="./references#CD011690-bbs2-0052" title="KDIGO . KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International ‐ Supplement2012;2(4):279‐335. ">KDIGO 2012</a>) recommend that in general ESAs should not be used to raise Hb levels &gt; 11.5 g/dL. </p> </section> <section id="CD011690-sec-0027"> <h3 class="title" id="CD011690-sec-0027">Why it is important to do this review</h3> <p>In a previous Cochrane systematic review, which included 15 RCTs, rHuEPO (epoetin alpha) significantly increased Hb (two studies) or haematocrit (HCT) levels (five studies) compared with placebo or no treatment and significantly reduced blood transfusion requirements (<a href="./references#CD011690-bbs2-0039" title="CodyJD , DalyC , CampbellMK , KhanI , RabindranathKS , ValeL , et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre‐dialysis patients. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD003266.pub2] ">Cody 2005</a>). Determining the ESA agent to be used should include assessment of the drug's pharmacodynamics, pharmacokinetics, route and frequency of administration, adverse effects, availability and any economic issues (<a href="./references#CD011690-bbs2-0052" title="KDIGO . KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International ‐ Supplement2012;2(4):279‐335. ">KDIGO 2012</a>). In most high income countries, the use of short‐acting ESAs (epoetin alpha, epoetin beta) in patients with CKD has been superseded by longer acting ESAs (darbepoetin, CERA) because of the reduced frequency of administration. In low income countries where newer longer acting ESAs are less likely to be accessible, clinicians may be limited to use short‐acting ESAs. The cost of using newer ESAs agents would have to be balanced against the costs and inconvenience of more frequent administration. Since the efficacy and safety of rHuEPO compared with placebo or no treatment has already been demonstrated (<a href="./references#CD011690-bbs2-0039" title="CodyJD , DalyC , CampbellMK , KhanI , RabindranathKS , ValeL , et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre‐dialysis patients. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD003266.pub2] ">Cody 2005</a>), this review aims to evaluate short‐acting ESAs (epoetin alpha, epoetin beta, other epoetins or epoetin biosimilars) in patients, both adults and children with CKD not on dialysis (CKD stages 2 to 5) with reference to route of administration (intravenous versus subcutaneous), frequency of administration, different doses and direct comparisons of different epoetins to provide additional information about the value of these agents for institutions where shorter acting ESAs are used. </p> <p>This review will not evaluate studies comparing short‐acting with longer acting ESAs in CKD, different longer acting ESAs in CKD, different routes of administration in dialysis patients or kidney transplant recipients and different Hb targets as these are subject of other Cochrane published or planned systematic reviews (<a href="./references#CD011690-bbs2-0048" title="HahnD , CodyJD , HodsonEM . Frequency of administration of erythropoiesis‐stimulating agents for the anaemia of end‐stage kidney disease in dialysis patients. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD003895.pub3] ">Hahn 2014</a>; <a href="./references#CD011690-bbs2-0062" title="PalmerSC , NandK , Dwi Nur HidayatiL , MunasingheA , NelsonC , KhafajiMM , et al. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD009904] ">Palmer 2012</a>; <a href="./references#CD011690-bbs2-0063" title="PalmerSC , SaglimbeneV , MavridisD , SalantiG , CraigJC , TonelliM , et al. Erythropoiesis‐stimulating agents for anaemia in adults with chronic kidney disease: a network meta‐analysis. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD010590.pub2] ">Palmer 2014a</a>; <a href="./references#CD011690-bbs2-0064" title="PalmerSC , SaglimbeneV , CraigJC , NavaneethanSD , StrippolliGF . Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD009297.pub2] ">Palmer 2014b</a>; <a href="./references#CD011690-bbs2-0073" title="StrippoliGF , NavaneethanSD , CraigJC , PalmerSC . Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD003967.pub2] ">Strippoli 2006</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011690-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011690-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011690-sec-0108">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011690-sec-0028"></div> <p>This review aimed to evaluate the benefits and harms of different routes, frequencies and doses of epoetins (epoetin alpha, epoetin beta and other short‐acting epoetins) for anaemia in adults and children with CKD not receiving dialysis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011690-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011690-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011690-sec-0109">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011690-sec-0029"></div> <section id="CD011690-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011690-sec-0031"> <h4 class="title">Types of studies</h4> <p>All RCTs and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at epoetins (short‐acting ESAs) for treatment of anaemia in patients with CKD not on dialysis. </p> </section> <section id="CD011690-sec-0032"> <h4 class="title">Types of participants</h4> <section id="CD011690-sec-0033"> <h5 class="title">Inclusion criteria</h5> <p>Patients of any age (adults and children) with anaemia due to CKD (stages 2 to 5) of any severity, who were not receiving dialysis, were included. The definitions of CKD and anaemia used in individual studies were used in this review. </p> </section> <section id="CD011690-sec-0034"> <h5 class="title">Exclusion criteria</h5> <p>Patients of any age receiving dialysis treatment. Patients receiving long‐acting ESAs or included in studies comparing shorter with longer acting ESAs were excluded. Kidney transplant recipients were also excluded. </p> </section> </section> <section id="CD011690-sec-0035"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD011690-list-0001"> <li> <p>Short‐acting ESAs including epoetins alpha (Eprex<sup>®</sup>, Procrit<sup>®</sup>, Epogen<sup>®</sup>), beta (Recormin<sup>®</sup>), delta (Dynepo<sup>®</sup>), epoetin theta (Biopoin<sup>®</sup>) and biosimilars of epoetin alpha (HX575, EPO‐ hexal<sup>®</sup>, Abseamed<sup>®</sup>), epoetin zeta (Silapo<sup>®</sup>, Retacrit<sup>®</sup>, Epoetin Hospira<sup>®</sup>) </p> </li> <li> <p>Short‐acting ESAs including epoetins with different routes of administration</p> </li> <li> <p>Short‐acting ESAs including epoetins used at different frequencies of administration</p> </li> <li> <p>Short‐acting ESAs including epoetins used at different doses</p> </li> <li> <p>Head‐to‐head comparisons of different short‐acting ESAs.</p> </li> </ul> </p> </section> <section id="CD011690-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD011690-sec-0037"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011690-list-0002"> <li> <p>Death</p> <ul id="CD011690-list-0003"> <li> <p>All‐cause mortality</p> </li> <li> <p>Mortality due to cardiac disease or cerebrovascular events</p> </li> </ul> </li> <li> <p>Measures of correction of anaemia</p> <ul id="CD011690-list-0004"> <li> <p>Values of Hb/HCT or change in Hb/HCT at the end of the study</p> </li> </ul> </li> <li> <p>Quality of life.</p> </li> </ol> </p> </section> <section id="CD011690-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011690-list-0005"> <li> <p>Hypertension and blood pressure outcomes</p> <ul id="CD011690-list-0006"> <li> <p>Hypertension (number of patients presenting one or more episodes of hypertension)</p> </li> <li> <p>Systolic blood pressure at end of treatment (mm Hg)</p> </li> <li> <p>Diastolic blood pressure at end of treatment (mm Hg).</p> </li> </ul> </li> <li> <p>Cardiovascular morbidity</p> </li> <li> <p>Cerebrovascular morbidity</p> </li> <li> <p>Adverse effects</p> <ul id="CD011690-list-0007"> <li> <p>Number needing blood transfusion</p> </li> <li> <p>Thrombotic events</p> </li> <li> <p>Number ceasing ESA for adverse effects</p> </li> <li> <p>Number of patients requiring hospitalisations for any cause</p> </li> <li> <p>Number of patients developing antibody‐mediated pure red cell aplasia</p> </li> <li> <p>Number of patients developing a malignancy.</p> </li> </ul> </li> <li> <p>Kidney function measures (GFR, serum creatinine (SCr), doubling of SCr) as reported by the authors of primary studies </p> </li> <li> <p>Need for iron supplementation.</p> </li> </ol> </p> </section> </section> </section> <section id="CD011690-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011690-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Specialised Register</a> up to 12 September 2016 through contact with the Information Specialist using search terms relevant to this review. The Specialised Register contains studies identified from several sources. </p> <p> <ol id="CD011690-list-0008"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register were identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>See <a href="./appendices#CD011690-sec-0094">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD011690-sec-0041"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD011690-list-0009"> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD011690-sec-0042"> <h3 class="title" id="CD011690-sec-0042">Data collection and analysis</h3> <section id="CD011690-sec-0043"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that may be relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable; however studies and reviews that might have included relevant data or information on studies were retained initially. Two authors independently assessed the retrieved abstracts and, if necessary the full text, of these studies to determine which studies satisfied the inclusion criteria. </p> </section> <section id="CD011690-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by at least two authors using standard data extraction forms. Where there was more than one publication of a study, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions these data were used. Any discrepancy between published versions was highlighted. </p> </section> <section id="CD011690-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD011690-bbs2-0050" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD011690-sec-0095">Appendix 2</a>). </p> <p> <ul id="CD011690-list-0010"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD011690-list-0011"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Were reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD011690-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (e.g. all‐cause mortality, adverse events, number needing transfusions) results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (e.g. final Hb/HCT or change in Hb/HCT, blood pressure, SCr), the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales had been used. </p> </section> <section id="CD011690-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>We included only data from the first period of treatment in cross‐over studies (<a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1002/14651858.CD009904/#CD009904-bbs2-0009" target="_blank">Higgins 2011</a>). Data expressed in different metrics were analysed using SMD. </p> </section> <section id="CD011690-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the original author was requested by written correspondence (e.g. emailing corresponding authors) and any relevant information obtained in this manner was included in the review. We aimed to analyse available data in meta‐analyses using intention‐to‐treat (ITT) data. However, where only ITT data were available graphically or were not provided and additional information could not be obtained from the study authors, per‐protocol (PP) data was used in analyses. </p> <p>We imputed a change‐from‐baseline standard deviation using an imputed correlation coefficient when sufficient data were available. </p> </section> <section id="CD011690-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi<sup>2</sup> test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I<sup>2</sup> test (<a href="./references#CD011690-bbs2-0049" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I<sup>2</sup> values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD011690-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>The search strategy applied aimed to reduce publication bias caused by lack of publication of studies with negative results. We investigated for publication bias using funnel plots if there were sufficient studies of each comparison (<a href="./references#CD011690-bbs2-0050" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD011690-sec-0051"> <h4 class="title">Data synthesis</h4> <p>Data were summarised using the random‐effects model but the fixed‐effect model was also used to ensure robustness of the model chosen. We qualitatively summarised data where insufficient data were available for meta‐analysis. Where there were multiple publications of the same study, all reports were reviewed to ensure that all details of methods and results were included. Qualitative review was conducted for adverse events and quality of life outcomes. </p> </section> <section id="CD011690-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was used to explore possible sources of heterogeneity (participants, interventions and study quality). Heterogeneity among participants could be related to age (adult versus children) or stage of CKD. Heterogeneity in interventions could be related to dose, duration or frequency of rHuEPO treatment or to the route of administration. . Where possible, the risk ratio with 95% CI was calculated for each adverse effect, either compared to no treatment or to another agent. </p> </section> <section id="CD011690-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses tested decisions where inclusion of a study may have altered the results of the meta‐analysis. In particular, sensitivity analysis may be used to test decisions where ITT and PP data were included in the same analyses. </p> <section id="CD011690-sec-0054"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD011690-bbs2-0069" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD011690-bbs2-0045" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD011690-bbs2-0070" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). We presented the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD011690-list-0012"> <li> <p>Epoetin alpha every 2 weeks compared to weekly for anaemia in CKD patients not receiving dialysis (<a href="./full#CD011690-tbl-0001">summary of findings Table for the main comparison</a>) </p> <ul id="CD011690-list-0013"> <li> <p>Final or change in Hb level (g/dL)</p> </li> <li> <p>Number reaching target Hb</p> </li> <li> <p>Number of deaths</p> </li> <li> <p>Number with adverse events: red blood cell transfusions, hypertension, thrombovascular events </p> </li> </ul> </li> <li> <p>Epoetin alfa every four weeks compared with every two weeks in CKD patients not receiving dialysis (<a href="./full#CD011690-tbl-0002">summary of findings Table 2</a>) </p> <ul id="CD011690-list-0014"> <li> <p>Final or change in Hb level (g/dL)</p> </li> <li> <p>Number reaching target Hb</p> </li> <li> <p>Number of deaths</p> </li> <li> <p>Number with adverse events: red blood cell transfusions, hypertension, thrombovascular events </p> </li> </ul> </li> <li> <p>Epoetin theta versus epoetin beta (<a href="./full#CD011690-tbl-0003">summary of findings Table 3</a>) </p> <ul id="CD011690-list-0015"> <li> <p>Final Hb (g/dL)</p> </li> <li> <p>Mean weekly epoetin dose (U/kg)</p> </li> <li> <p>Number of deaths</p> </li> <li> <p>Number with adverse events: hypertension, red blood cell transfusions, discontinuation of therapy. </p> </li> </ul> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011690-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011690-sec-0055"></div> <section id="CD011690-sec-0056"> <h3 class="title">Description of studies</h3> <section id="CD011690-sec-0057"> <h4 class="title">Results of the search</h4> <p>Seventy‐three reports were identified from the search to 12 September 2016. After title and abstract screening 22 reports were excluded. Full‐text review was carried out the remaining 51 reports. Fourteen studies (30 reports) (<a href="./references#CD011690-bbs2-0001" title="AggarwalHK , KaushikG , SinghS , NandN , SinghM . Comparison of efficacy of subcutaneous versus intravenous erythropoeitin in anaemia of chronic renal failure [abstract no: 227]. Journal of the Association of Physicians of India2001;49(Jan). [CENTRAL: CN‐01094842] AggarwalHK , NandN , SinghS , SinghM , KaushikG . Comparative efficacy of subcutaneous versus intravenous dose of erythropoietin in pre‐dialysis patients of chronic renal failure. Journal of Indian Academy of Clinical Medicine2002;3(1):46‐50. [CENTRAL: CN‐00689631] ">Aggarwal 2002</a>; <a href="./references#CD011690-bbs2-0002" title="AkibaT , KoshikawaS , MimuraN , MaedaT , KRN5702 Pre‐Dialysis Study Group. Randomized double‐blind study of subcutaneous recombinant human erythropoietin in predialysis uraemic patients [abstract]. Nephrology Dialysis Transplantation1992;7(7):765. [CENTRAL: CN‐00260735] ">Akiba 1992</a>; <a href="./references#CD011690-bbs2-0003" title="AmonO , Muller‐WiefelDE , DanielK , EifeR , LeititisJ , StolpeHJ . Is S.C. erythropoietin (rhEPO) treatment thrice per week superior to an application once per week? [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 ‐ Sep 4; Jerusalem, Israel. 1992:C143. [CENTRAL: CN‐00483004] ">Amon 1992</a>; <a href="./references#CD011690-bbs2-0004" title="FrenkenLA , VerberckmoesR , MichielsenP , KoeneRA . Efficacy and tolerance of treatment with recombinant‐human erythropoietin in chronic renal failure (pre‐dialysis) patients. Nephrology Dialysis Transplantation1989;4(9):782‐6. [MEDLINE: 2516609] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant human erythropoietin in end‐stage renal disease (predialysis) patients [abstract]. Nephrology Dialysis Transplantation1988;3(4):495. [CENTRAL: CN‐00260377] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant‐human erythropoietin in end‐state renal disease (pre‐dialysis) patients [abstract]. Kidney International1988;34(4):558. [CENTRAL: CN‐00644276] KoeneR , FrenkenL . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Nefrologia1990;10(Suppl 2):131‐6. KoeneRA , FrenkenLA . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Contributions to Nephrology1990;87:105‐12. [MEDLINE: 2093536] ">Frenken 1989</a>; <a href="./references#CD011690-bbs2-0005" title="GertzB , KesP , EssaianA , BiasP , BuchnerA , ZellnerD . Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre‐dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research &amp; Opinion2012;28(7):1101‐10. [MEDLINE: 22533679] ">Gertz 2012</a>; <a href="./references#CD011690-bbs2-0006" title="Haag‐WeberM , EckardtKU , HorlWH , RogerSD , VetterA , RothK . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin‐alpha (HX575) in non‐dialysis patients with renal anemia: a multi‐center, randomized, double‐blind study. Clinical Nephrology2012;77(1):8‐17. [MEDLINE: 22185963] ">Haag‐Weber 2012</a>; <a href="./references#CD011690-bbs2-0007" title="KnebelW , PalmenM , DowellJA , GastonguayM . Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. Journal of Clinical Pharmacology2008;48(7):837‐48. [MEDLINE: 18490498] ">Knebel 2008</a>; <a href="./references#CD011690-bbs2-0008" title="KronborgJ , WillassenY , StromsaetherCE , PaulsenD . Pain after subcutaneous injection of erythropoietin (EPO). A comparison of two different preparations [abstract]. Journal of the American Society of Nephrology1994;5(3):460. ">Kronborg 1994</a>; <a href="./references#CD011690-bbs2-0009" title="MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP . Epoetin delta corrects and maintains haemoglobin in pre‐end stage renal disease [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:140. [CENTRAL: CN‐00461317] MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP , European HMR4396 Study Group. Novel human erythropoietin corrects and maintains hemoglobin in pre‐end stage renal disease (ESRD) when administered twice weekly subcutaneously [abstract no: A0384]. Journal of the American Society of Nephrology2000;11(Sept):71A. [MEDLINE: CN‐00794723] PrattRD . Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis [abstract no: TH‐PO377]. Journal of the American Society of Nephrology2006;17(Abstracts):187A. [CENTRAL: CN‐00765050] ">Mignon 2000</a>; <a href="./references#CD011690-bbs2-0010" title="PergolaPE , GartenbergG , FuM , BowersP . Extended dosing regimens of epoetin alfa (EPO) in EPO‐naive, pre‐dialysis subjects with anemia of chronic kidney disease (CKD): an open‐label randomized study [abstract no: F‐PO1833]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):523A. [CENTRAL: CN‐00747297] PergolaPE , GartenbergG , FuM , WolfsonM , RaoS , BowersP . A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2009;4(11):1731‐40. [MEDLINE: 19808215] ">Pergola 2009</a>; <a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0013" title="SohmiyaM , KakibaT , KatoY . Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. European Journal of Endocrinology1998;139(4):367‐70. [MEDLINE: 9820611] ">Sohmiya 1998</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>) were included and 17 studies (19 reports) (<a href="./references#CD011690-bbs2-0015" title="BrownCD , KieranM , DosunmuBV , ZhaoZ , LarsonRH , FriedmanEA . Raised hematocrit (HCT) persists six‐weeks after stopping treatment with human recombinant erythropoietin (r‐HuEPO) in azotemic anemic patients [abstract]. Kidney International1988;33(1):184. [CENTRAL: CN‐00602117] ">Brown 1988</a>; <a href="./references#CD011690-bbs2-0016" title="ClyneN , JogestrandT . Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron1992;60(4):390‐6. [MEDLINE: 1584314] ">Clyne 1992</a>; <a href="./references#CD011690-bbs2-0017" title="DuliegeAM , MacdougallI , DuncanN , WesselsD , IwashitaJ , SchatzP , et al. Hematide, a synthetic peptide‐based erythropoiesis stimulating agent (ESA), demonstrates erythropoietic activity in a phase 2 single dose, dose escalating study in patients with chronic kidney disease (CKD) [abstract no: 3532]. Blood2005;106(11 Pt 1):986. [CENTRAL: CN‐00624867] DuliegeAM , MacdougallIC , GoldsmithD , WesselsD , IwashitaJ , SchatzP , et al. HematideTM, a synthetic peptide‐based erythropoiesis stimulating agent (ESA), demonstrates erythropoietic activity in single dose studies in normal healthy volunteers (HV) and in patients with chronic kidney disease (CKD) [abstract no: SP420]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv155. [CENTRAL: CN‐00797702] ">Duliege 2005</a>; <a href="./references#CD011690-bbs2-0018" title="FurukawaA , NumataA , ImagawaA , KaifuY , SumikuraT , MiyakeH , et al. Study of recombinant human erythropoietin treatment on the anemia of predialysis patients. Nippon Jinzo Gakkai Shi [Japanese Journal of Nephrology]1992, (6):693‐700. [MEDLINE: 1479709] ">Furukawa 1992</a>; <a href="./references#CD011690-bbs2-0019" title="LiQF , MaQY , ZhuCF . Effect of combination of bushen jianpi recipe and erythropoietin on serum tumor necrosis factor alpha in patients with anemia. Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional &amp; Western Medicine]2004;24(2):106‐8. [MEDLINE: 15015438] ">Li 2004</a>; <a href="./references#CD011690-bbs2-0020" title="MeloniC , TozzoC , RossiV , BorziM , FlaminiM , GrottaBD , et al. Early anaemia correction with EPO: one year effects on LVH and progression of chronic renal failure (CRF) in predialysis patients (PTS) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):157. [CENTRAL: CN‐00446732] ">Meloni 2003</a>; <a href="./references#CD011690-bbs2-0021" title="NCT00240734 . A randomized, double‐blind, placebo‐controlled study evaluating weekly epoetin alfa (PROCRIT) administration on hemoglobin response and safety in diabetic subjects with the anemia of chronic kidney disease (CKD). www.clinicaltrials.gov/ct2/show/NCT00240734 (accessed 15 December 2016). ">NCT00240734</a>; <a href="./references#CD011690-bbs2-0022" title="BabaT . Correction and maintenance study of subcutaneous injections of R744 to predialysis patients (phase III, comparative study in comparison with epoetin beta). www.clinicaltrials.gov/ct2/show/NCT00492427 (accessed 15 December 2016). ">NCT00492427</a>; <a href="./references#CD011690-bbs2-0023" title="WangAYM . A prospective randomised controlled trial to study the effects of recombinant human erythropoietin on the progression of atherosclerosis, cardiovascular function, nutrition and residual renal function in pre‐dialysis chronic renal failure patients. www.clinicaltrials.gov/ct2/show/NCT00563355 (accessed 15 December 2016). ">NCT00563355</a>; <a href="./references#CD011690-bbs2-0024" title="PatelM , ThimonsDG , WinstonJL , LangholffW , McGowanT . An open‐label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. Journal of the American Medical Directors Association2012;13(3):244‐8. [MEDLINE: 21450214] ">Patel 2012</a>; <a href="./references#CD011690-bbs2-0025" title="PriorJE , TerzianA , SchwartzAB , KimKE , MintzGS , KahnSB . Prolonged RBC survival and hematopoietic response to recombinant human erythropoietin (rHuEPO) in chronic renal failure (CRF) [abstract]. Kidney International1989;35(1):318. [CENTRAL: CN‐00766056] SchwartzAB , MintzGS , KimKE , PriorJE , KahnSB . Recombinant human erythropoietin (rHuEPO) increases MAP, TPRI and systolic and diastolic dysfunction with increased impedance to LV ejection due to increased HCT and RBC mass in PTS with CRF [abstract]. Kidney International1989;35(1):334. [CENTRAL: CN‐00766227] ">Schwartz 1989</a>; <a href="./references#CD011690-bbs2-0026" title="ShaheenFA , Al‐AqeilNA , BadawiL , SheikhIA , ShalabiNM , AdikuW , et al. Correction of anemia by erythropoietin in pre‐dialysis patients. Saudi Kidney Diseases &amp; Transplantation Bulletin1983;4(3):215‐9. [CENTRAL: CN‐00525736] ">Shaheen 1983</a>; <a href="./references#CD011690-bbs2-0027" title="SinghNP , AggarwalL , SinghT , AnuradhaS , KohliR . Anaemia, iron studies and erythropoietin in patients of chronic renal failure. Journal of the Association of Physicians of India1999;47(3):284‐90. [MEDLINE: 10999121] ">Singh 1999</a>; <a href="./references#CD011690-bbs2-0028" title="TeehanBP , BenzRL , SiglerMH , BrownJM . Early intervention with recombinant human erythropoietin therapy. Seminars in Nephrology1990;10(2 Suppl 1):28‐34. [MEDLINE: 2192414] ">Teehan 1990</a>; <a href="./references#CD011690-bbs2-0029" title="TeplanV , SchuckO , MengerovaO , StollovaM . Recombinant human erythropoietin (r‐hu EPO) and keto amino acids (KA) in predialysis: an accelerated metabolic effect [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:503. [CENTRAL: CN‐00509503] ">Teplan 1995</a>; <a href="./references#CD011690-bbs2-0030" title="YamazakiC , WatanabeY , SakamotoN . Pharmacokinetic study of recombinant human erythropoietin treatment in pre‐dialysis end stage renal disease patients. Nippon Jinzo Gakkai Shi [Japanese Journal of Nephrology]1993;35(11):1233‐42. [MEDLINE: 8139135] ">Yamazaki 1993</a>; <a href="./references#CD011690-bbs2-0031" title="ZhengFL , BiZQ , YangZP , LiXW , PuYF , DuanL . Effect of administration of low doses of rhuEPO in predialysis patients [abstract]. 9th Asian Colloquium in Nephrology; 1992 May 17‐21; Seoul, Korea. 1992:175. [CENTRAL: CN‐00462065] ">Zheng 1992</a>) were excluded. Two recently completed studies (<a href="./references#CD011690-bbs2-0032" title="NCT01576341 . Open label, single arm, multicenter study to evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in pre‐dialysis and dialysis patients. www.clinicaltrials.gov/ct2/show/results/NCT01576341 (accessed 15 December 2016). ">NCT01576341</a>; <a href="./references#CD011690-bbs2-0033" title="NCT01693029 . Randomized, double‐blind, parallel group, multicenter study to evaluate the efficacy and safety of HX575 epoetin alfa vs. US licensed epoetin alfa (Epogen®/Procrit®) in the treatment of anemia associated with chronic kidney disease. www.clinicaltrials.gov/ct2/show/NCT01693029 (accessed 15 December 2016). ">NCT01693029</a>) will be assessed in a future update of this review (<a href="#CD011690-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011690-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011690-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011690-sec-0058"> <h4 class="title">Included studies</h4> <p>The 14 studies were divided into four treatment comparisons groups (<a href="#CD011690-fig-0001">Figure 1</a>). </p> <section id="CD011690-sec-0059"> <h5 class="title">Epoetin alpha or beta administered at different frequencies using the same total dose</h5> <p>Six studies (<a href="./references#CD011690-bbs2-0003" title="AmonO , Muller‐WiefelDE , DanielK , EifeR , LeititisJ , StolpeHJ . Is S.C. erythropoietin (rhEPO) treatment thrice per week superior to an application once per week? [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 ‐ Sep 4; Jerusalem, Israel. 1992:C143. [CENTRAL: CN‐00483004] ">Amon 1992</a>; <a href="./references#CD011690-bbs2-0010" title="PergolaPE , GartenbergG , FuM , BowersP . Extended dosing regimens of epoetin alfa (EPO) in EPO‐naive, pre‐dialysis subjects with anemia of chronic kidney disease (CKD): an open‐label randomized study [abstract no: F‐PO1833]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):523A. [CENTRAL: CN‐00747297] PergolaPE , GartenbergG , FuM , WolfsonM , RaoS , BowersP . A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2009;4(11):1731‐40. [MEDLINE: 19808215] ">Pergola 2009</a>; <a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0013" title="SohmiyaM , KakibaT , KatoY . Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. European Journal of Endocrinology1998;139(4):367‐70. [MEDLINE: 9820611] ">Sohmiya 1998</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>) (1613 enrolled/1585 evaluated participants) compared epoetin alpha or beta at different frequencies using the same total dose in each group. </p> <p> <ul id="CD011690-list-0016"> <li> <p>Four studies (<a href="./references#CD011690-bbs2-0010" title="PergolaPE , GartenbergG , FuM , BowersP . Extended dosing regimens of epoetin alfa (EPO) in EPO‐naive, pre‐dialysis subjects with anemia of chronic kidney disease (CKD): an open‐label randomized study [abstract no: F‐PO1833]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):523A. [CENTRAL: CN‐00747297] PergolaPE , GartenbergG , FuM , WolfsonM , RaoS , BowersP . A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2009;4(11):1731‐40. [MEDLINE: 19808215] ">Pergola 2009</a>; <a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>) with 840 enrolled (838 analysed) participants compared epoetin alpha administered at 10,000IU per week with 20,000IU given every two weeks. </p> </li> <li> <p>Three studies (<a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>) with 724 analysed participants also compared epoetin alpha administered at 20,000 IU every two weeks with 40,000 IU every four weeks. </p> </li> <li> <p><a href="./references#CD011690-bbs2-0003" title="AmonO , Muller‐WiefelDE , DanielK , EifeR , LeititisJ , StolpeHJ . Is S.C. erythropoietin (rhEPO) treatment thrice per week superior to an application once per week? [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 ‐ Sep 4; Jerusalem, Israel. 1992:C143. [CENTRAL: CN‐00483004] ">Amon 1992</a> (22 enrolled, 18 evaluated) compared subcutaneous epoetin alpha 50 IU/kg three times a week with 150 IU/kg given once weekly in children. </p> </li> <li> <p><a href="./references#CD011690-bbs2-0013" title="SohmiyaM , KakibaT , KatoY . Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. European Journal of Endocrinology1998;139(4):367‐70. [MEDLINE: 9820611] ">Sohmiya 1998</a> (5 enrolled, 5 evaluated) compared continuous infusion of epoetin beta with weekly subcutaneous injections for four weeks using the same total dose in each group in a cross over study. </p> </li> </ul> </p> </section> <section id="CD011690-sec-0060"> <h5 class="title">Epoetin alpha administered at the same frequency using different total doses</h5> <p>Three studies (<a href="./references#CD011690-bbs2-0002" title="AkibaT , KoshikawaS , MimuraN , MaedaT , KRN5702 Pre‐Dialysis Study Group. Randomized double‐blind study of subcutaneous recombinant human erythropoietin in predialysis uraemic patients [abstract]. Nephrology Dialysis Transplantation1992;7(7):765. [CENTRAL: CN‐00260735] ">Akiba 1992</a>; <a href="./references#CD011690-bbs2-0004" title="FrenkenLA , VerberckmoesR , MichielsenP , KoeneRA . Efficacy and tolerance of treatment with recombinant‐human erythropoietin in chronic renal failure (pre‐dialysis) patients. Nephrology Dialysis Transplantation1989;4(9):782‐6. [MEDLINE: 2516609] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant human erythropoietin in end‐stage renal disease (predialysis) patients [abstract]. Nephrology Dialysis Transplantation1988;3(4):495. [CENTRAL: CN‐00260377] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant‐human erythropoietin in end‐state renal disease (pre‐dialysis) patients [abstract]. Kidney International1988;34(4):558. [CENTRAL: CN‐00644276] KoeneR , FrenkenL . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Nefrologia1990;10(Suppl 2):131‐6. KoeneRA , FrenkenLA . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Contributions to Nephrology1990;87:105‐12. [MEDLINE: 2093536] ">Frenken 1989</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>) (339 enrolled/333 analysed participants) compared epoetin alpha at different doses but at the same frequencies. </p> <p> <ul id="CD011690-list-0017"> <li> <p><a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a> (150 enrolled/144 evaluated) compared 20,000 IU given four weekly with 40 000IU given four weekly </p> </li> <li> <p><a href="./references#CD011690-bbs2-0002" title="AkibaT , KoshikawaS , MimuraN , MaedaT , KRN5702 Pre‐Dialysis Study Group. Randomized double‐blind study of subcutaneous recombinant human erythropoietin in predialysis uraemic patients [abstract]. Nephrology Dialysis Transplantation1992;7(7):765. [CENTRAL: CN‐00260735] ">Akiba 1992</a> (165 enrolled and evaluated) compared 3000 IU, 6000 IU and 12 000 IU given weekly to three groups </p> </li> <li> <p><a href="./references#CD011690-bbs2-0004" title="FrenkenLA , VerberckmoesR , MichielsenP , KoeneRA . Efficacy and tolerance of treatment with recombinant‐human erythropoietin in chronic renal failure (pre‐dialysis) patients. Nephrology Dialysis Transplantation1989;4(9):782‐6. [MEDLINE: 2516609] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant human erythropoietin in end‐stage renal disease (predialysis) patients [abstract]. Nephrology Dialysis Transplantation1988;3(4):495. [CENTRAL: CN‐00260377] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant‐human erythropoietin in end‐state renal disease (pre‐dialysis) patients [abstract]. Kidney International1988;34(4):558. [CENTRAL: CN‐00644276] KoeneR , FrenkenL . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Nefrologia1990;10(Suppl 2):131‐6. KoeneRA , FrenkenLA . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Contributions to Nephrology1990;87:105‐12. [MEDLINE: 2093536] ">Frenken 1989</a> (24 enrolled and evaluated) compared 50 IU/Kg, 100 IU/kg and 150 IU/Kg given three times weekly. </p> </li> </ul> </p> </section> <section id="CD011690-sec-0061"> <h5 class="title">Epoetin alpha intravenous versus subcutaneous administration</h5> <p> <ul id="CD011690-list-0018"> <li> <p><a href="./references#CD011690-bbs2-0001" title="AggarwalHK , KaushikG , SinghS , NandN , SinghM . Comparison of efficacy of subcutaneous versus intravenous erythropoeitin in anaemia of chronic renal failure [abstract no: 227]. Journal of the Association of Physicians of India2001;49(Jan). [CENTRAL: CN‐01094842] AggarwalHK , NandN , SinghS , SinghM , KaushikG . Comparative efficacy of subcutaneous versus intravenous dose of erythropoietin in pre‐dialysis patients of chronic renal failure. Journal of Indian Academy of Clinical Medicine2002;3(1):46‐50. [CENTRAL: CN‐00689631] ">Aggarwal 2002</a> (20 participants enrolled and evaluated) compared subcutaneous with intravenous administration of epoetin alpha. </p> </li> </ul> </p> </section> <section id="CD011690-sec-0062"> <h5 class="title">Epoetin alpha or beta versus other epoetins or biosimilars of epoetin alpha</h5> <p>Five studies <a href="./references#CD011690-bbs2-0005" title="GertzB , KesP , EssaianA , BiasP , BuchnerA , ZellnerD . Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre‐dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research &amp; Opinion2012;28(7):1101‐10. [MEDLINE: 22533679] ">Gertz 2012</a>; <a href="./references#CD011690-bbs2-0006" title="Haag‐WeberM , EckardtKU , HorlWH , RogerSD , VetterA , RothK . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin‐alpha (HX575) in non‐dialysis patients with renal anemia: a multi‐center, randomized, double‐blind study. Clinical Nephrology2012;77(1):8‐17. [MEDLINE: 22185963] ">Haag‐Weber 2012</a>; <a href="./references#CD011690-bbs2-0007" title="KnebelW , PalmenM , DowellJA , GastonguayM . Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. Journal of Clinical Pharmacology2008;48(7):837‐48. [MEDLINE: 18490498] ">Knebel 2008</a>;<a href="./references#CD011690-bbs2-0008" title="KronborgJ , WillassenY , StromsaetherCE , PaulsenD . Pain after subcutaneous injection of erythropoietin (EPO). A comparison of two different preparations [abstract]. Journal of the American Society of Nephrology1994;5(3):460. ">Kronborg 1994</a>; <a href="./references#CD011690-bbs2-0009" title="MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP . Epoetin delta corrects and maintains haemoglobin in pre‐end stage renal disease [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:140. [CENTRAL: CN‐00461317] MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP , European HMR4396 Study Group. Novel human erythropoietin corrects and maintains hemoglobin in pre‐end stage renal disease (ESRD) when administered twice weekly subcutaneously [abstract no: A0384]. Journal of the American Society of Nephrology2000;11(Sept):71A. [MEDLINE: CN‐00794723] PrattRD . Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis [abstract no: TH‐PO377]. Journal of the American Society of Nephrology2006;17(Abstracts):187A. [CENTRAL: CN‐00765050] ">Mignon 2000</a>) (794 participants) were included in this comparison. </p> <p> <ul id="CD011690-list-0019"> <li> <p><a href="./references#CD011690-bbs2-0005" title="GertzB , KesP , EssaianA , BiasP , BuchnerA , ZellnerD . Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre‐dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research &amp; Opinion2012;28(7):1101‐10. [MEDLINE: 22533679] ">Gertz 2012</a> (288 enrolled and evaluated) compared weekly subcutaneous epoetin theta with epoetin beta </p> </li> <li> <p><a href="./references#CD011690-bbs2-0006" title="Haag‐WeberM , EckardtKU , HorlWH , RogerSD , VetterA , RothK . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin‐alpha (HX575) in non‐dialysis patients with renal anemia: a multi‐center, randomized, double‐blind study. Clinical Nephrology2012;77(1):8‐17. [MEDLINE: 22185963] ">Haag‐Weber 2012</a> (337 enrolled) compared a bio‐similar HX575 epoetin alpha with epoetin alpha (Eprex). This study was terminated due to the development of neutralising antibodies in two patients receiving subcutaneous HX575. Efficacy could not be assessed because the authors did not provide the number of patients, who contributed data to efficacy endpoints. Limited safety data were available. </p> </li> <li> <p>Two studies (<a href="./references#CD011690-bbs2-0009" title="MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP . Epoetin delta corrects and maintains haemoglobin in pre‐end stage renal disease [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:140. [CENTRAL: CN‐00461317] MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP , European HMR4396 Study Group. Novel human erythropoietin corrects and maintains hemoglobin in pre‐end stage renal disease (ESRD) when administered twice weekly subcutaneously [abstract no: A0384]. Journal of the American Society of Nephrology2000;11(Sept):71A. [MEDLINE: CN‐00794723] PrattRD . Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis [abstract no: TH‐PO377]. Journal of the American Society of Nephrology2006;17(Abstracts):187A. [CENTRAL: CN‐00765050] ">Mignon 2000</a>, <a href="./references#CD011690-bbs2-0007" title="KnebelW , PalmenM , DowellJA , GastonguayM . Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. Journal of Clinical Pharmacology2008;48(7):837‐48. [MEDLINE: 18490498] ">Knebel 2008</a>) (140 enrolled) compared subcutaneous administration of epoetin delta with epoetin alpha. Both studies were terminated before completion when the pharmaceutical company ceased production of epoetin delta for commercial reasons and no data were available. </p> </li> <li> <p><a href="./references#CD011690-bbs2-0008" title="KronborgJ , WillassenY , StromsaetherCE , PaulsenD . Pain after subcutaneous injection of erythropoietin (EPO). A comparison of two different preparations [abstract]. Journal of the American Society of Nephrology1994;5(3):460. ">Kronborg 1994</a> (29 enrolled and evaluated) compared pain scores in participants treated with epoetin alpha or epoetin beta given subcutaneously using a visual analogue scale (VAS) and a verbal descriptive scale (VDS). As the results included a median with inter‐quartile ranges the data could not be included in a meta‐analysis. </p> </li> </ul> </p> </section> </section> <section id="CD011690-sec-0063"> <h4 class="title">Excluded studies</h4> <p>Seventeen studies were excluded. Eleven studies were ineligible as they compared a short‐acting ESA with placebo or no treatment (<a href="./references#CD011690-bbs2-0015" title="BrownCD , KieranM , DosunmuBV , ZhaoZ , LarsonRH , FriedmanEA . Raised hematocrit (HCT) persists six‐weeks after stopping treatment with human recombinant erythropoietin (r‐HuEPO) in azotemic anemic patients [abstract]. Kidney International1988;33(1):184. [CENTRAL: CN‐00602117] ">Brown 1988</a>; <a href="./references#CD011690-bbs2-0016" title="ClyneN , JogestrandT . Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron1992;60(4):390‐6. [MEDLINE: 1584314] ">Clyne 1992</a>; <a href="./references#CD011690-bbs2-0020" title="MeloniC , TozzoC , RossiV , BorziM , FlaminiM , GrottaBD , et al. Early anaemia correction with EPO: one year effects on LVH and progression of chronic renal failure (CRF) in predialysis patients (PTS) [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):157. [CENTRAL: CN‐00446732] ">Meloni 2003</a>; <a href="./references#CD011690-bbs2-0021" title="NCT00240734 . A randomized, double‐blind, placebo‐controlled study evaluating weekly epoetin alfa (PROCRIT) administration on hemoglobin response and safety in diabetic subjects with the anemia of chronic kidney disease (CKD). www.clinicaltrials.gov/ct2/show/NCT00240734 (accessed 15 December 2016). ">NCT00240734</a>; <a href="./references#CD011690-bbs2-0023" title="WangAYM . A prospective randomised controlled trial to study the effects of recombinant human erythropoietin on the progression of atherosclerosis, cardiovascular function, nutrition and residual renal function in pre‐dialysis chronic renal failure patients. www.clinicaltrials.gov/ct2/show/NCT00563355 (accessed 15 December 2016). ">NCT00563355</a>; <a href="./references#CD011690-bbs2-0024" title="PatelM , ThimonsDG , WinstonJL , LangholffW , McGowanT . An open‐label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. Journal of the American Medical Directors Association2012;13(3):244‐8. [MEDLINE: 21450214] ">Patel 2012</a>; <a href="./references#CD011690-bbs2-0025" title="PriorJE , TerzianA , SchwartzAB , KimKE , MintzGS , KahnSB . Prolonged RBC survival and hematopoietic response to recombinant human erythropoietin (rHuEPO) in chronic renal failure (CRF) [abstract]. Kidney International1989;35(1):318. [CENTRAL: CN‐00766056] SchwartzAB , MintzGS , KimKE , PriorJE , KahnSB . Recombinant human erythropoietin (rHuEPO) increases MAP, TPRI and systolic and diastolic dysfunction with increased impedance to LV ejection due to increased HCT and RBC mass in PTS with CRF [abstract]. Kidney International1989;35(1):334. [CENTRAL: CN‐00766227] ">Schwartz 1989</a>; <a href="./references#CD011690-bbs2-0026" title="ShaheenFA , Al‐AqeilNA , BadawiL , SheikhIA , ShalabiNM , AdikuW , et al. Correction of anemia by erythropoietin in pre‐dialysis patients. Saudi Kidney Diseases &amp; Transplantation Bulletin1983;4(3):215‐9. [CENTRAL: CN‐00525736] ">Shaheen 1983</a>; <a href="./references#CD011690-bbs2-0027" title="SinghNP , AggarwalL , SinghT , AnuradhaS , KohliR . Anaemia, iron studies and erythropoietin in patients of chronic renal failure. Journal of the Association of Physicians of India1999;47(3):284‐90. [MEDLINE: 10999121] ">Singh 1999</a>; <a href="./references#CD011690-bbs2-0028" title="TeehanBP , BenzRL , SiglerMH , BrownJM . Early intervention with recombinant human erythropoietin therapy. Seminars in Nephrology1990;10(2 Suppl 1):28‐34. [MEDLINE: 2192414] ">Teehan 1990</a>; <a href="./references#CD011690-bbs2-0029" title="TeplanV , SchuckO , MengerovaO , StollovaM . Recombinant human erythropoietin (r‐hu EPO) and keto amino acids (KA) in predialysis: an accelerated metabolic effect [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:503. [CENTRAL: CN‐00509503] ">Teplan 1995</a>). <a href="./references#CD011690-bbs2-0022" title="BabaT . Correction and maintenance study of subcutaneous injections of R744 to predialysis patients (phase III, comparative study in comparison with epoetin beta). www.clinicaltrials.gov/ct2/show/NCT00492427 (accessed 15 December 2016). ">NCT00492427</a> compared short‐acting ESA with the long acting ESA, darbepoetin and this study is included in another review (<a href="./references#CD011690-bbs2-0064" title="PalmerSC , SaglimbeneV , CraigJC , NavaneethanSD , StrippolliGF . Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD009297.pub2] ">Palmer 2014b</a>). Three studies assessed other interventions, or were pharmacokinetic studies (<a href="./references#CD011690-bbs2-0017" title="DuliegeAM , MacdougallI , DuncanN , WesselsD , IwashitaJ , SchatzP , et al. Hematide, a synthetic peptide‐based erythropoiesis stimulating agent (ESA), demonstrates erythropoietic activity in a phase 2 single dose, dose escalating study in patients with chronic kidney disease (CKD) [abstract no: 3532]. Blood2005;106(11 Pt 1):986. [CENTRAL: CN‐00624867] DuliegeAM , MacdougallIC , GoldsmithD , WesselsD , IwashitaJ , SchatzP , et al. HematideTM, a synthetic peptide‐based erythropoiesis stimulating agent (ESA), demonstrates erythropoietic activity in single dose studies in normal healthy volunteers (HV) and in patients with chronic kidney disease (CKD) [abstract no: SP420]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv155. [CENTRAL: CN‐00797702] ">Duliege 2005</a>; <a href="./references#CD011690-bbs2-0018" title="FurukawaA , NumataA , ImagawaA , KaifuY , SumikuraT , MiyakeH , et al. Study of recombinant human erythropoietin treatment on the anemia of predialysis patients. Nippon Jinzo Gakkai Shi [Japanese Journal of Nephrology]1992, (6):693‐700. [MEDLINE: 1479709] ">Furukawa 1992</a>; <a href="./references#CD011690-bbs2-0019" title="LiQF , MaQY , ZhuCF . Effect of combination of bushen jianpi recipe and erythropoietin on serum tumor necrosis factor alpha in patients with anemia. Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional &amp; Western Medicine]2004;24(2):106‐8. [MEDLINE: 15015438] ">Li 2004</a>). Randomisation was unclear in two studies (<a href="./references#CD011690-bbs2-0030" title="YamazakiC , WatanabeY , SakamotoN . Pharmacokinetic study of recombinant human erythropoietin treatment in pre‐dialysis end stage renal disease patients. Nippon Jinzo Gakkai Shi [Japanese Journal of Nephrology]1993;35(11):1233‐42. [MEDLINE: 8139135] ">Yamazaki 1993</a>; <a href="./references#CD011690-bbs2-0031" title="ZhengFL , BiZQ , YangZP , LiXW , PuYF , DuanL . Effect of administration of low doses of rhuEPO in predialysis patients [abstract]. 9th Asian Colloquium in Nephrology; 1992 May 17‐21; Seoul, Korea. 1992:175. [CENTRAL: CN‐00462065] ">Zheng 1992</a>). </p> </section> </section> <section id="CD011690-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>The results of the risk of bias assessment are shown in <a href="#CD011690-fig-0002">Figure 2</a> and <a href="#CD011690-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011690-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011690-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011690-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011690-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011690-sec-0065"> <h4 class="title">Allocation</h4> <p>Sequence generation was deemed at low risk of bias in three studies (<a href="./references#CD011690-bbs2-0005" title="GertzB , KesP , EssaianA , BiasP , BuchnerA , ZellnerD . Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre‐dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research &amp; Opinion2012;28(7):1101‐10. [MEDLINE: 22533679] ">Gertz 2012</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>) and unclear in the remaining eleven studies (<a href="./references#CD011690-bbs2-0001" title="AggarwalHK , KaushikG , SinghS , NandN , SinghM . Comparison of efficacy of subcutaneous versus intravenous erythropoeitin in anaemia of chronic renal failure [abstract no: 227]. Journal of the Association of Physicians of India2001;49(Jan). [CENTRAL: CN‐01094842] AggarwalHK , NandN , SinghS , SinghM , KaushikG . Comparative efficacy of subcutaneous versus intravenous dose of erythropoietin in pre‐dialysis patients of chronic renal failure. Journal of Indian Academy of Clinical Medicine2002;3(1):46‐50. [CENTRAL: CN‐00689631] ">Aggarwal 2002</a>; <a href="./references#CD011690-bbs2-0002" title="AkibaT , KoshikawaS , MimuraN , MaedaT , KRN5702 Pre‐Dialysis Study Group. Randomized double‐blind study of subcutaneous recombinant human erythropoietin in predialysis uraemic patients [abstract]. Nephrology Dialysis Transplantation1992;7(7):765. [CENTRAL: CN‐00260735] ">Akiba 1992</a>; <a href="./references#CD011690-bbs2-0003" title="AmonO , Muller‐WiefelDE , DanielK , EifeR , LeititisJ , StolpeHJ . Is S.C. erythropoietin (rhEPO) treatment thrice per week superior to an application once per week? [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 ‐ Sep 4; Jerusalem, Israel. 1992:C143. [CENTRAL: CN‐00483004] ">Amon 1992</a>; <a href="./references#CD011690-bbs2-0004" title="FrenkenLA , VerberckmoesR , MichielsenP , KoeneRA . Efficacy and tolerance of treatment with recombinant‐human erythropoietin in chronic renal failure (pre‐dialysis) patients. Nephrology Dialysis Transplantation1989;4(9):782‐6. [MEDLINE: 2516609] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant human erythropoietin in end‐stage renal disease (predialysis) patients [abstract]. Nephrology Dialysis Transplantation1988;3(4):495. [CENTRAL: CN‐00260377] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant‐human erythropoietin in end‐state renal disease (pre‐dialysis) patients [abstract]. Kidney International1988;34(4):558. [CENTRAL: CN‐00644276] KoeneR , FrenkenL . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Nefrologia1990;10(Suppl 2):131‐6. KoeneRA , FrenkenLA . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Contributions to Nephrology1990;87:105‐12. [MEDLINE: 2093536] ">Frenken 1989</a>; <a href="./references#CD011690-bbs2-0006" title="Haag‐WeberM , EckardtKU , HorlWH , RogerSD , VetterA , RothK . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin‐alpha (HX575) in non‐dialysis patients with renal anemia: a multi‐center, randomized, double‐blind study. Clinical Nephrology2012;77(1):8‐17. [MEDLINE: 22185963] ">Haag‐Weber 2012</a>; <a href="./references#CD011690-bbs2-0007" title="KnebelW , PalmenM , DowellJA , GastonguayM . Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. Journal of Clinical Pharmacology2008;48(7):837‐48. [MEDLINE: 18490498] ">Knebel 2008</a>; <a href="./references#CD011690-bbs2-0008" title="KronborgJ , WillassenY , StromsaetherCE , PaulsenD . Pain after subcutaneous injection of erythropoietin (EPO). A comparison of two different preparations [abstract]. Journal of the American Society of Nephrology1994;5(3):460. ">Kronborg 1994</a>; <a href="./references#CD011690-bbs2-0009" title="MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP . Epoetin delta corrects and maintains haemoglobin in pre‐end stage renal disease [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:140. [CENTRAL: CN‐00461317] MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP , European HMR4396 Study Group. Novel human erythropoietin corrects and maintains hemoglobin in pre‐end stage renal disease (ESRD) when administered twice weekly subcutaneously [abstract no: A0384]. Journal of the American Society of Nephrology2000;11(Sept):71A. [MEDLINE: CN‐00794723] PrattRD . Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis [abstract no: TH‐PO377]. Journal of the American Society of Nephrology2006;17(Abstracts):187A. [CENTRAL: CN‐00765050] ">Mignon 2000</a>; <a href="./references#CD011690-bbs2-0010" title="PergolaPE , GartenbergG , FuM , BowersP . Extended dosing regimens of epoetin alfa (EPO) in EPO‐naive, pre‐dialysis subjects with anemia of chronic kidney disease (CKD): an open‐label randomized study [abstract no: F‐PO1833]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):523A. [CENTRAL: CN‐00747297] PergolaPE , GartenbergG , FuM , WolfsonM , RaoS , BowersP . A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2009;4(11):1731‐40. [MEDLINE: 19808215] ">Pergola 2009</a>; <a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0013" title="SohmiyaM , KakibaT , KatoY . Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. European Journal of Endocrinology1998;139(4):367‐70. [MEDLINE: 9820611] ">Sohmiya 1998</a>). </p> <p>Allocation concealment was at low risk of bias in two studies (<a href="./references#CD011690-bbs2-0005" title="GertzB , KesP , EssaianA , BiasP , BuchnerA , ZellnerD . Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre‐dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research &amp; Opinion2012;28(7):1101‐10. [MEDLINE: 22533679] ">Gertz 2012</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>) and unclear in the remaining twelve studies (<a href="./references#CD011690-bbs2-0001" title="AggarwalHK , KaushikG , SinghS , NandN , SinghM . Comparison of efficacy of subcutaneous versus intravenous erythropoeitin in anaemia of chronic renal failure [abstract no: 227]. Journal of the Association of Physicians of India2001;49(Jan). [CENTRAL: CN‐01094842] AggarwalHK , NandN , SinghS , SinghM , KaushikG . Comparative efficacy of subcutaneous versus intravenous dose of erythropoietin in pre‐dialysis patients of chronic renal failure. Journal of Indian Academy of Clinical Medicine2002;3(1):46‐50. [CENTRAL: CN‐00689631] ">Aggarwal 2002</a>; <a href="./references#CD011690-bbs2-0002" title="AkibaT , KoshikawaS , MimuraN , MaedaT , KRN5702 Pre‐Dialysis Study Group. Randomized double‐blind study of subcutaneous recombinant human erythropoietin in predialysis uraemic patients [abstract]. Nephrology Dialysis Transplantation1992;7(7):765. [CENTRAL: CN‐00260735] ">Akiba 1992</a>; <a href="./references#CD011690-bbs2-0003" title="AmonO , Muller‐WiefelDE , DanielK , EifeR , LeititisJ , StolpeHJ . Is S.C. erythropoietin (rhEPO) treatment thrice per week superior to an application once per week? [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 ‐ Sep 4; Jerusalem, Israel. 1992:C143. [CENTRAL: CN‐00483004] ">Amon 1992</a>; <a href="./references#CD011690-bbs2-0004" title="FrenkenLA , VerberckmoesR , MichielsenP , KoeneRA . Efficacy and tolerance of treatment with recombinant‐human erythropoietin in chronic renal failure (pre‐dialysis) patients. Nephrology Dialysis Transplantation1989;4(9):782‐6. [MEDLINE: 2516609] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant human erythropoietin in end‐stage renal disease (predialysis) patients [abstract]. Nephrology Dialysis Transplantation1988;3(4):495. [CENTRAL: CN‐00260377] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant‐human erythropoietin in end‐state renal disease (pre‐dialysis) patients [abstract]. Kidney International1988;34(4):558. [CENTRAL: CN‐00644276] KoeneR , FrenkenL . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Nefrologia1990;10(Suppl 2):131‐6. KoeneRA , FrenkenLA . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Contributions to Nephrology1990;87:105‐12. [MEDLINE: 2093536] ">Frenken 1989</a>; <a href="./references#CD011690-bbs2-0006" title="Haag‐WeberM , EckardtKU , HorlWH , RogerSD , VetterA , RothK . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin‐alpha (HX575) in non‐dialysis patients with renal anemia: a multi‐center, randomized, double‐blind study. Clinical Nephrology2012;77(1):8‐17. [MEDLINE: 22185963] ">Haag‐Weber 2012</a>; <a href="./references#CD011690-bbs2-0007" title="KnebelW , PalmenM , DowellJA , GastonguayM . Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. Journal of Clinical Pharmacology2008;48(7):837‐48. [MEDLINE: 18490498] ">Knebel 2008</a>; <a href="./references#CD011690-bbs2-0008" title="KronborgJ , WillassenY , StromsaetherCE , PaulsenD . Pain after subcutaneous injection of erythropoietin (EPO). A comparison of two different preparations [abstract]. Journal of the American Society of Nephrology1994;5(3):460. ">Kronborg 1994</a>; <a href="./references#CD011690-bbs2-0009" title="MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP . Epoetin delta corrects and maintains haemoglobin in pre‐end stage renal disease [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:140. [CENTRAL: CN‐00461317] MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP , European HMR4396 Study Group. Novel human erythropoietin corrects and maintains hemoglobin in pre‐end stage renal disease (ESRD) when administered twice weekly subcutaneously [abstract no: A0384]. Journal of the American Society of Nephrology2000;11(Sept):71A. [MEDLINE: CN‐00794723] PrattRD . Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis [abstract no: TH‐PO377]. Journal of the American Society of Nephrology2006;17(Abstracts):187A. [CENTRAL: CN‐00765050] ">Mignon 2000</a>; <a href="./references#CD011690-bbs2-0010" title="PergolaPE , GartenbergG , FuM , BowersP . Extended dosing regimens of epoetin alfa (EPO) in EPO‐naive, pre‐dialysis subjects with anemia of chronic kidney disease (CKD): an open‐label randomized study [abstract no: F‐PO1833]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):523A. [CENTRAL: CN‐00747297] PergolaPE , GartenbergG , FuM , WolfsonM , RaoS , BowersP . A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2009;4(11):1731‐40. [MEDLINE: 19808215] ">Pergola 2009</a>; <a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0013" title="SohmiyaM , KakibaT , KatoY . Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. European Journal of Endocrinology1998;139(4):367‐70. [MEDLINE: 9820611] ">Sohmiya 1998</a>). </p> </section> <section id="CD011690-sec-0066"> <h4 class="title">Blinding</h4> <p>Only one study (<a href="./references#CD011690-bbs2-0005" title="GertzB , KesP , EssaianA , BiasP , BuchnerA , ZellnerD . Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre‐dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research &amp; Opinion2012;28(7):1101‐10. [MEDLINE: 22533679] ">Gertz 2012</a>) was blinded and considered to be at low risk of bias for performance bias. Ten studies were not blinded and determined as high risk of performance bias (<a href="./references#CD011690-bbs2-0001" title="AggarwalHK , KaushikG , SinghS , NandN , SinghM . Comparison of efficacy of subcutaneous versus intravenous erythropoeitin in anaemia of chronic renal failure [abstract no: 227]. Journal of the Association of Physicians of India2001;49(Jan). [CENTRAL: CN‐01094842] AggarwalHK , NandN , SinghS , SinghM , KaushikG . Comparative efficacy of subcutaneous versus intravenous dose of erythropoietin in pre‐dialysis patients of chronic renal failure. Journal of Indian Academy of Clinical Medicine2002;3(1):46‐50. [CENTRAL: CN‐00689631] ">Aggarwal 2002</a>; <a href="./references#CD011690-bbs2-0003" title="AmonO , Muller‐WiefelDE , DanielK , EifeR , LeititisJ , StolpeHJ . Is S.C. erythropoietin (rhEPO) treatment thrice per week superior to an application once per week? [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 ‐ Sep 4; Jerusalem, Israel. 1992:C143. [CENTRAL: CN‐00483004] ">Amon 1992</a>; <a href="./references#CD011690-bbs2-0004" title="FrenkenLA , VerberckmoesR , MichielsenP , KoeneRA . Efficacy and tolerance of treatment with recombinant‐human erythropoietin in chronic renal failure (pre‐dialysis) patients. Nephrology Dialysis Transplantation1989;4(9):782‐6. [MEDLINE: 2516609] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant human erythropoietin in end‐stage renal disease (predialysis) patients [abstract]. Nephrology Dialysis Transplantation1988;3(4):495. [CENTRAL: CN‐00260377] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant‐human erythropoietin in end‐state renal disease (pre‐dialysis) patients [abstract]. Kidney International1988;34(4):558. [CENTRAL: CN‐00644276] KoeneR , FrenkenL . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Nefrologia1990;10(Suppl 2):131‐6. KoeneRA , FrenkenLA . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Contributions to Nephrology1990;87:105‐12. [MEDLINE: 2093536] ">Frenken 1989</a>; <a href="./references#CD011690-bbs2-0006" title="Haag‐WeberM , EckardtKU , HorlWH , RogerSD , VetterA , RothK . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin‐alpha (HX575) in non‐dialysis patients with renal anemia: a multi‐center, randomized, double‐blind study. Clinical Nephrology2012;77(1):8‐17. [MEDLINE: 22185963] ">Haag‐Weber 2012</a>; <a href="./references#CD011690-bbs2-0007" title="KnebelW , PalmenM , DowellJA , GastonguayM . Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. Journal of Clinical Pharmacology2008;48(7):837‐48. [MEDLINE: 18490498] ">Knebel 2008</a>; <a href="./references#CD011690-bbs2-0010" title="PergolaPE , GartenbergG , FuM , BowersP . Extended dosing regimens of epoetin alfa (EPO) in EPO‐naive, pre‐dialysis subjects with anemia of chronic kidney disease (CKD): an open‐label randomized study [abstract no: F‐PO1833]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):523A. [CENTRAL: CN‐00747297] PergolaPE , GartenbergG , FuM , WolfsonM , RaoS , BowersP . A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2009;4(11):1731‐40. [MEDLINE: 19808215] ">Pergola 2009</a>; <a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0013" title="SohmiyaM , KakibaT , KatoY . Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. European Journal of Endocrinology1998;139(4):367‐70. [MEDLINE: 9820611] ">Sohmiya 1998</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>). Blinding was unclear in the remaining three studies (<a href="./references#CD011690-bbs2-0002" title="AkibaT , KoshikawaS , MimuraN , MaedaT , KRN5702 Pre‐Dialysis Study Group. Randomized double‐blind study of subcutaneous recombinant human erythropoietin in predialysis uraemic patients [abstract]. Nephrology Dialysis Transplantation1992;7(7):765. [CENTRAL: CN‐00260735] ">Akiba 1992</a>; <a href="./references#CD011690-bbs2-0008" title="KronborgJ , WillassenY , StromsaetherCE , PaulsenD . Pain after subcutaneous injection of erythropoietin (EPO). A comparison of two different preparations [abstract]. Journal of the American Society of Nephrology1994;5(3):460. ">Kronborg 1994</a>; <a href="./references#CD011690-bbs2-0009" title="MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP . Epoetin delta corrects and maintains haemoglobin in pre‐end stage renal disease [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:140. [CENTRAL: CN‐00461317] MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP , European HMR4396 Study Group. Novel human erythropoietin corrects and maintains hemoglobin in pre‐end stage renal disease (ESRD) when administered twice weekly subcutaneously [abstract no: A0384]. Journal of the American Society of Nephrology2000;11(Sept):71A. [MEDLINE: CN‐00794723] PrattRD . Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis [abstract no: TH‐PO377]. Journal of the American Society of Nephrology2006;17(Abstracts):187A. [CENTRAL: CN‐00765050] ">Mignon 2000</a>). </p> <p>As the primary outcomes (final Hb level or change in Hb level) in all studies were based on laboratory assessment, and therefore unlikely to be influenced by blinding, 13 studies were deemed to be at low risk of detection bias. The study by <a href="./references#CD011690-bbs2-0008" title="KronborgJ , WillassenY , StromsaetherCE , PaulsenD . Pain after subcutaneous injection of erythropoietin (EPO). A comparison of two different preparations [abstract]. Journal of the American Society of Nephrology1994;5(3):460. ">Kronborg 1994</a> was considered at unclear risk of detection bias; it assessed pain scores and was said to be double‐blinded though no information was provided as to how this was performed. </p> </section> <section id="CD011690-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>Eight studies were determined to be at low risk of attrition bias (<a href="./references#CD011690-bbs2-0001" title="AggarwalHK , KaushikG , SinghS , NandN , SinghM . Comparison of efficacy of subcutaneous versus intravenous erythropoeitin in anaemia of chronic renal failure [abstract no: 227]. Journal of the Association of Physicians of India2001;49(Jan). [CENTRAL: CN‐01094842] AggarwalHK , NandN , SinghS , SinghM , KaushikG . Comparative efficacy of subcutaneous versus intravenous dose of erythropoietin in pre‐dialysis patients of chronic renal failure. Journal of Indian Academy of Clinical Medicine2002;3(1):46‐50. [CENTRAL: CN‐00689631] ">Aggarwal 2002</a>; <a href="./references#CD011690-bbs2-0005" title="GertzB , KesP , EssaianA , BiasP , BuchnerA , ZellnerD . Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre‐dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research &amp; Opinion2012;28(7):1101‐10. [MEDLINE: 22533679] ">Gertz 2012</a>; <a href="./references#CD011690-bbs2-0008" title="KronborgJ , WillassenY , StromsaetherCE , PaulsenD . Pain after subcutaneous injection of erythropoietin (EPO). A comparison of two different preparations [abstract]. Journal of the American Society of Nephrology1994;5(3):460. ">Kronborg 1994</a>; <a href="./references#CD011690-bbs2-0010" title="PergolaPE , GartenbergG , FuM , BowersP . Extended dosing regimens of epoetin alfa (EPO) in EPO‐naive, pre‐dialysis subjects with anemia of chronic kidney disease (CKD): an open‐label randomized study [abstract no: F‐PO1833]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):523A. [CENTRAL: CN‐00747297] PergolaPE , GartenbergG , FuM , WolfsonM , RaoS , BowersP . A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2009;4(11):1731‐40. [MEDLINE: 19808215] ">Pergola 2009</a>; <a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0013" title="SohmiyaM , KakibaT , KatoY . Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. European Journal of Endocrinology1998;139(4):367‐70. [MEDLINE: 9820611] ">Sohmiya 1998</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>). Four studies were at high risk of bias because meta‐analyses could not be performed as total patient numbers were not provided (<a href="./references#CD011690-bbs2-0002" title="AkibaT , KoshikawaS , MimuraN , MaedaT , KRN5702 Pre‐Dialysis Study Group. Randomized double‐blind study of subcutaneous recombinant human erythropoietin in predialysis uraemic patients [abstract]. Nephrology Dialysis Transplantation1992;7(7):765. [CENTRAL: CN‐00260735] ">Akiba 1992</a>; <a href="./references#CD011690-bbs2-0006" title="Haag‐WeberM , EckardtKU , HorlWH , RogerSD , VetterA , RothK . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin‐alpha (HX575) in non‐dialysis patients with renal anemia: a multi‐center, randomized, double‐blind study. Clinical Nephrology2012;77(1):8‐17. [MEDLINE: 22185963] ">Haag‐Weber 2012</a>; <a href="./references#CD011690-bbs2-0007" title="KnebelW , PalmenM , DowellJA , GastonguayM . Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. Journal of Clinical Pharmacology2008;48(7):837‐48. [MEDLINE: 18490498] ">Knebel 2008</a>) or because more than 10% patients were excluded from analysis (<a href="./references#CD011690-bbs2-0003" title="AmonO , Muller‐WiefelDE , DanielK , EifeR , LeititisJ , StolpeHJ . Is S.C. erythropoietin (rhEPO) treatment thrice per week superior to an application once per week? [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 ‐ Sep 4; Jerusalem, Israel. 1992:C143. [CENTRAL: CN‐00483004] ">Amon 1992</a>). Attrition bias was deemed unclear in the remaining two studies (<a href="./references#CD011690-bbs2-0004" title="FrenkenLA , VerberckmoesR , MichielsenP , KoeneRA . Efficacy and tolerance of treatment with recombinant‐human erythropoietin in chronic renal failure (pre‐dialysis) patients. Nephrology Dialysis Transplantation1989;4(9):782‐6. [MEDLINE: 2516609] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant human erythropoietin in end‐stage renal disease (predialysis) patients [abstract]. Nephrology Dialysis Transplantation1988;3(4):495. [CENTRAL: CN‐00260377] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant‐human erythropoietin in end‐state renal disease (pre‐dialysis) patients [abstract]. Kidney International1988;34(4):558. [CENTRAL: CN‐00644276] KoeneR , FrenkenL . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Nefrologia1990;10(Suppl 2):131‐6. KoeneRA , FrenkenLA . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Contributions to Nephrology1990;87:105‐12. [MEDLINE: 2093536] ">Frenken 1989</a>; <a href="./references#CD011690-bbs2-0009" title="MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP . Epoetin delta corrects and maintains haemoglobin in pre‐end stage renal disease [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:140. [CENTRAL: CN‐00461317] MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP , European HMR4396 Study Group. Novel human erythropoietin corrects and maintains hemoglobin in pre‐end stage renal disease (ESRD) when administered twice weekly subcutaneously [abstract no: A0384]. Journal of the American Society of Nephrology2000;11(Sept):71A. [MEDLINE: CN‐00794723] PrattRD . Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis [abstract no: TH‐PO377]. Journal of the American Society of Nephrology2006;17(Abstracts):187A. [CENTRAL: CN‐00765050] ">Mignon 2000</a>). </p> </section> <section id="CD011690-sec-0068"> <h4 class="title">Selective reporting</h4> <p>Studies that did not provide data on final or change in Hb and on patient‐centred outcomes including adverse events such as blood transfusions, vascular access complications or all‐cause mortality were considered to be at high risk for selective reporting. Eight studies were considered at high risk of reporting bias (<a href="./references#CD011690-bbs2-0001" title="AggarwalHK , KaushikG , SinghS , NandN , SinghM . Comparison of efficacy of subcutaneous versus intravenous erythropoeitin in anaemia of chronic renal failure [abstract no: 227]. Journal of the Association of Physicians of India2001;49(Jan). [CENTRAL: CN‐01094842] AggarwalHK , NandN , SinghS , SinghM , KaushikG . Comparative efficacy of subcutaneous versus intravenous dose of erythropoietin in pre‐dialysis patients of chronic renal failure. Journal of Indian Academy of Clinical Medicine2002;3(1):46‐50. [CENTRAL: CN‐00689631] ">Aggarwal 2002</a>; <a href="./references#CD011690-bbs2-0002" title="AkibaT , KoshikawaS , MimuraN , MaedaT , KRN5702 Pre‐Dialysis Study Group. Randomized double‐blind study of subcutaneous recombinant human erythropoietin in predialysis uraemic patients [abstract]. Nephrology Dialysis Transplantation1992;7(7):765. [CENTRAL: CN‐00260735] ">Akiba 1992</a>; <a href="./references#CD011690-bbs2-0003" title="AmonO , Muller‐WiefelDE , DanielK , EifeR , LeititisJ , StolpeHJ . Is S.C. erythropoietin (rhEPO) treatment thrice per week superior to an application once per week? [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 ‐ Sep 4; Jerusalem, Israel. 1992:C143. [CENTRAL: CN‐00483004] ">Amon 1992</a>; <a href="./references#CD011690-bbs2-0006" title="Haag‐WeberM , EckardtKU , HorlWH , RogerSD , VetterA , RothK . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin‐alpha (HX575) in non‐dialysis patients with renal anemia: a multi‐center, randomized, double‐blind study. Clinical Nephrology2012;77(1):8‐17. [MEDLINE: 22185963] ">Haag‐Weber 2012</a>; <a href="./references#CD011690-bbs2-0007" title="KnebelW , PalmenM , DowellJA , GastonguayM . Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. Journal of Clinical Pharmacology2008;48(7):837‐48. [MEDLINE: 18490498] ">Knebel 2008</a>; <a href="./references#CD011690-bbs2-0008" title="KronborgJ , WillassenY , StromsaetherCE , PaulsenD . Pain after subcutaneous injection of erythropoietin (EPO). A comparison of two different preparations [abstract]. Journal of the American Society of Nephrology1994;5(3):460. ">Kronborg 1994</a>; <a href="./references#CD011690-bbs2-0009" title="MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP . Epoetin delta corrects and maintains haemoglobin in pre‐end stage renal disease [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:140. [CENTRAL: CN‐00461317] MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP , European HMR4396 Study Group. Novel human erythropoietin corrects and maintains hemoglobin in pre‐end stage renal disease (ESRD) when administered twice weekly subcutaneously [abstract no: A0384]. Journal of the American Society of Nephrology2000;11(Sept):71A. [MEDLINE: CN‐00794723] PrattRD . Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis [abstract no: TH‐PO377]. Journal of the American Society of Nephrology2006;17(Abstracts):187A. [CENTRAL: CN‐00765050] ">Mignon 2000</a>; <a href="./references#CD011690-bbs2-0013" title="SohmiyaM , KakibaT , KatoY . Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. European Journal of Endocrinology1998;139(4):367‐70. [MEDLINE: 9820611] ">Sohmiya 1998</a>). Six studies (<a href="./references#CD011690-bbs2-0003" title="AmonO , Muller‐WiefelDE , DanielK , EifeR , LeititisJ , StolpeHJ . Is S.C. erythropoietin (rhEPO) treatment thrice per week superior to an application once per week? [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 ‐ Sep 4; Jerusalem, Israel. 1992:C143. [CENTRAL: CN‐00483004] ">Amon 1992</a>; <a href="./references#CD011690-bbs2-0005" title="GertzB , KesP , EssaianA , BiasP , BuchnerA , ZellnerD . Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre‐dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research &amp; Opinion2012;28(7):1101‐10. [MEDLINE: 22533679] ">Gertz 2012</a>; <a href="./references#CD011690-bbs2-0010" title="PergolaPE , GartenbergG , FuM , BowersP . Extended dosing regimens of epoetin alfa (EPO) in EPO‐naive, pre‐dialysis subjects with anemia of chronic kidney disease (CKD): an open‐label randomized study [abstract no: F‐PO1833]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):523A. [CENTRAL: CN‐00747297] PergolaPE , GartenbergG , FuM , WolfsonM , RaoS , BowersP . A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2009;4(11):1731‐40. [MEDLINE: 19808215] ">Pergola 2009</a>; <a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>) were assessed at low risk for selective reporting. </p> </section> <section id="CD011690-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>Only two studies were assessed at free of other potential bias sources (<a href="./references#CD011690-bbs2-0004" title="FrenkenLA , VerberckmoesR , MichielsenP , KoeneRA . Efficacy and tolerance of treatment with recombinant‐human erythropoietin in chronic renal failure (pre‐dialysis) patients. Nephrology Dialysis Transplantation1989;4(9):782‐6. [MEDLINE: 2516609] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant human erythropoietin in end‐stage renal disease (predialysis) patients [abstract]. Nephrology Dialysis Transplantation1988;3(4):495. [CENTRAL: CN‐00260377] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant‐human erythropoietin in end‐state renal disease (pre‐dialysis) patients [abstract]. Kidney International1988;34(4):558. [CENTRAL: CN‐00644276] KoeneR , FrenkenL . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Nefrologia1990;10(Suppl 2):131‐6. KoeneRA , FrenkenLA . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Contributions to Nephrology1990;87:105‐12. [MEDLINE: 2093536] ">Frenken 1989</a>; <a href="./references#CD011690-bbs2-0013" title="SohmiyaM , KakibaT , KatoY . Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. European Journal of Endocrinology1998;139(4):367‐70. [MEDLINE: 9820611] ">Sohmiya 1998</a>). Eight studies were industry funded and determined as at high risk of bias (<a href="./references#CD011690-bbs2-0005" title="GertzB , KesP , EssaianA , BiasP , BuchnerA , ZellnerD . Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre‐dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research &amp; Opinion2012;28(7):1101‐10. [MEDLINE: 22533679] ">Gertz 2012</a>; <a href="./references#CD011690-bbs2-0006" title="Haag‐WeberM , EckardtKU , HorlWH , RogerSD , VetterA , RothK . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin‐alpha (HX575) in non‐dialysis patients with renal anemia: a multi‐center, randomized, double‐blind study. Clinical Nephrology2012;77(1):8‐17. [MEDLINE: 22185963] ">Haag‐Weber 2012</a>; <a href="./references#CD011690-bbs2-0007" title="KnebelW , PalmenM , DowellJA , GastonguayM . Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. Journal of Clinical Pharmacology2008;48(7):837‐48. [MEDLINE: 18490498] ">Knebel 2008</a>; <a href="./references#CD011690-bbs2-0009" title="MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP . Epoetin delta corrects and maintains haemoglobin in pre‐end stage renal disease [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:140. [CENTRAL: CN‐00461317] MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP , European HMR4396 Study Group. Novel human erythropoietin corrects and maintains hemoglobin in pre‐end stage renal disease (ESRD) when administered twice weekly subcutaneously [abstract no: A0384]. Journal of the American Society of Nephrology2000;11(Sept):71A. [MEDLINE: CN‐00794723] PrattRD . Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis [abstract no: TH‐PO377]. Journal of the American Society of Nephrology2006;17(Abstracts):187A. [CENTRAL: CN‐00765050] ">Mignon 2000</a>; <a href="./references#CD011690-bbs2-0010" title="PergolaPE , GartenbergG , FuM , BowersP . Extended dosing regimens of epoetin alfa (EPO) in EPO‐naive, pre‐dialysis subjects with anemia of chronic kidney disease (CKD): an open‐label randomized study [abstract no: F‐PO1833]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):523A. [CENTRAL: CN‐00747297] PergolaPE , GartenbergG , FuM , WolfsonM , RaoS , BowersP . A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2009;4(11):1731‐40. [MEDLINE: 19808215] ">Pergola 2009</a>; <a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>). In the remaining four studies it was unclear whether the study was free of other potential sources of bias (<a href="./references#CD011690-bbs2-0001" title="AggarwalHK , KaushikG , SinghS , NandN , SinghM . Comparison of efficacy of subcutaneous versus intravenous erythropoeitin in anaemia of chronic renal failure [abstract no: 227]. Journal of the Association of Physicians of India2001;49(Jan). [CENTRAL: CN‐01094842] AggarwalHK , NandN , SinghS , SinghM , KaushikG . Comparative efficacy of subcutaneous versus intravenous dose of erythropoietin in pre‐dialysis patients of chronic renal failure. Journal of Indian Academy of Clinical Medicine2002;3(1):46‐50. [CENTRAL: CN‐00689631] ">Aggarwal 2002</a>; <a href="./references#CD011690-bbs2-0002" title="AkibaT , KoshikawaS , MimuraN , MaedaT , KRN5702 Pre‐Dialysis Study Group. Randomized double‐blind study of subcutaneous recombinant human erythropoietin in predialysis uraemic patients [abstract]. Nephrology Dialysis Transplantation1992;7(7):765. [CENTRAL: CN‐00260735] ">Akiba 1992</a>; <a href="./references#CD011690-bbs2-0003" title="AmonO , Muller‐WiefelDE , DanielK , EifeR , LeititisJ , StolpeHJ . Is S.C. erythropoietin (rhEPO) treatment thrice per week superior to an application once per week? [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 ‐ Sep 4; Jerusalem, Israel. 1992:C143. [CENTRAL: CN‐00483004] ">Amon 1992</a>; <a href="./references#CD011690-bbs2-0008" title="KronborgJ , WillassenY , StromsaetherCE , PaulsenD . Pain after subcutaneous injection of erythropoietin (EPO). A comparison of two different preparations [abstract]. Journal of the American Society of Nephrology1994;5(3):460. ">Kronborg 1994</a>). </p> </section> </section> <section id="CD011690-sec-0070"> <h3 class="title" id="CD011690-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD011690-tbl-0001"><b>Summary of findings for the main comparison</b> Epoetin alpha every 2 weeks versus to weekly for anaemia in CKD patients not receiving dialysis</a>; <a href="./full#CD011690-tbl-0002"><b>Summary of findings 2</b> Epoetin alfa every four weeks versus with every two weeks in CKD patients not receiving dialysis</a>; <a href="./full#CD011690-tbl-0003"><b>Summary of findings 3</b> Epoetin theta versus epoetin beta in CKD patients not receiving dialysis</a> </p> <section id="CD011690-sec-0071"> <h4 class="title">Epoetin alpha administered at different frequencies using the same total dose</h4> <p>Six studies investigated this comparison (<a href="./references#CD011690-bbs2-0003" title="AmonO , Muller‐WiefelDE , DanielK , EifeR , LeititisJ , StolpeHJ . Is S.C. erythropoietin (rhEPO) treatment thrice per week superior to an application once per week? [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 ‐ Sep 4; Jerusalem, Israel. 1992:C143. [CENTRAL: CN‐00483004] ">Amon 1992</a>; <a href="./references#CD011690-bbs2-0010" title="PergolaPE , GartenbergG , FuM , BowersP . Extended dosing regimens of epoetin alfa (EPO) in EPO‐naive, pre‐dialysis subjects with anemia of chronic kidney disease (CKD): an open‐label randomized study [abstract no: F‐PO1833]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):523A. [CENTRAL: CN‐00747297] PergolaPE , GartenbergG , FuM , WolfsonM , RaoS , BowersP . A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2009;4(11):1731‐40. [MEDLINE: 19808215] ">Pergola 2009</a>; <a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0013" title="SohmiyaM , KakibaT , KatoY . Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. European Journal of Endocrinology1998;139(4):367‐70. [MEDLINE: 9820611] ">Sohmiya 1998</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>). </p> <section id="CD011690-sec-0072"> <h5 class="title">Epoetin alpha weekly versus every two weeks using same total dose of epoetin</h5> <p>In meta‐analyses of four non‐inferiority studies (<a href="./references#CD011690-bbs2-0010" title="PergolaPE , GartenbergG , FuM , BowersP . Extended dosing regimens of epoetin alfa (EPO) in EPO‐naive, pre‐dialysis subjects with anemia of chronic kidney disease (CKD): an open‐label randomized study [abstract no: F‐PO1833]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):523A. [CENTRAL: CN‐00747297] PergolaPE , GartenbergG , FuM , WolfsonM , RaoS , BowersP . A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2009;4(11):1731‐40. [MEDLINE: 19808215] ">Pergola 2009</a>; <a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>), final Hb levels (<a href="./references#CD011690-fig-0004" title="">Analysis 1.1</a> (4 studies, 785 participants): MD ‐0.20 g/dL, 95% CI ‐0.33 to ‐0.07) and the number achieving target Hb were statistically significantly higher in patients receiving weekly doses compared with two weekly doses (<a href="./references#CD011690-fig-0005" title="">Analysis 1.2</a> (4 studies, 798 participants): RR 0.96, 95% CI 0.93 to 0.99). The differences were not considered to be clinically significant. No significant heterogeneity was noted. </p> <p>There were no significant difference in all‐cause mortality (<a href="./references#CD011690-fig-0006" title="">Analysis 1.3</a> (4 studies, 838 participants): RR 0.89, 95% CI 0.38 to 2.07), the number requiring transfusion (<a href="./references#CD011690-fig-0007" title="">Analysis 1.4</a>.1 (3 studies, 580 participants): RR 1.56, 95% CI 0.71 to 3.45), the number with hypertension (<a href="./references#CD011690-fig-0007" title="">Analysis 1.4</a>.2 (4 studies, 838 participants): RR 0.85, 95% CI 0.55 to 1.32), the number with thrombovascular complications <a href="./references#CD011690-fig-0007" title="">Analysis 1.4</a>.3 (4 studies, 838 participants): RR 1.41, 95% CI 0.67 to 3.00) or the number discontinuing therapy due to adverse effects (<a href="./references#CD011690-fig-0007" title="">Analysis 1.4</a>.4 (1 study, 258 participants): RR 0.98, 95% CI 0.20 to 4.79). </p> <p>No neutralising antibodies were detected in study participants in <a href="./references#CD011690-bbs2-0010" title="PergolaPE , GartenbergG , FuM , BowersP . Extended dosing regimens of epoetin alfa (EPO) in EPO‐naive, pre‐dialysis subjects with anemia of chronic kidney disease (CKD): an open‐label randomized study [abstract no: F‐PO1833]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):523A. [CENTRAL: CN‐00747297] PergolaPE , GartenbergG , FuM , WolfsonM , RaoS , BowersP . A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2009;4(11):1731‐40. [MEDLINE: 19808215] ">Pergola 2009</a> and <a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>. Most of the deaths were due to cardiovascular complications reflecting the underlying cardiovascular morbidity of the population studied. Only one study (<a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>) performed quality of life (QOL) assessments and reported no statistical differences in the final QOL scores between groups receiving epoetin once weekly or two weekly. </p> </section> <section id="CD011690-sec-0073"> <h5 class="title">Epoetin alpha every two weeks versus every four weeks using same total dose of epoetin</h5> <p>In meta‐analyses of three non‐inferiority studies (<a href="./references#CD011690-bbs2-0011" title="PergolaP , GartenbergG , FuM , BowersP , SunS . Every 2 and 4 week dosing with epoetin alfa is non‐inferior to once weekly dosing in pre‐dialysis subjects with anemia of chronic kidney disease: an open‐label randomized study [abstract no: F‐PO1095]. Journal of the American Society of Nephrology2009;20(Abstracts):364A. PergolaPE , GartenbergG , FuM , SunS , WolfsonM , BowersP . A randomized controlled study comparing once‐weekly to every‐2‐week and every‐4‐week dosing of epoetin alfa in CKD patients with anemia. Clinical Journal of the American Society of Nephrology: CJASN2010;5(4):598‐606. [MEDLINE: 20185602] ">Pergola 2010</a>; <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>), there were no significant differences in final Hb levels (<a href="./references#CD011690-fig-0008" title="">Analysis 2.1</a> (3 studies, 671 participants): MD ‐0.16 g/dL, 95% CI ‐0.43 to 0.10; I<sup>2</sup> = 63%) or in the number reaching target Hb levels (<a href="./references#CD011690-fig-0009" title="">Analysis 2.2</a> (3 studies, 687 participants): RR 0.95, 95% CI 0.84 to 1.07) with dosing every two weeks compared with every four weeks. There was unexplained marked heterogeneity between these studies. </p> <p>There were no significant differences in all‐cause mortality (<a href="./references#CD011690-fig-0010" title="">Analysis 2.3</a> (3 studies, 724 participants): RR 0.95, 95% CI 0.33 to 2.75), the number requiring transfusions (<a href="./references#CD011690-fig-0011" title="">Analysis 2.4</a>.I (2 studies, 470 participants): RR 1.26, 95% CI 0.53 to 2.98); the number with hypertension (<a href="./references#CD011690-fig-0011" title="">Analysis 2.4</a>.2 (3 studies, 724 participants): RR 1.02, 95% CI 0.62 to 1.69); and the number with thrombovascular complications (<a href="./references#CD011690-fig-0011" title="">Analysis 2.4</a>.3 (3 studies, 724 participants): RR 1.02, 95% CI 0.39 to 2.68). <a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a> noted no difference in final QOL scores between participants who received epoetins at two weekly or four weekly intervals. </p> </section> <section id="CD011690-sec-0074"> <h5 class="title">Other studies</h5> <p><a href="./references#CD011690-bbs2-0003" title="AmonO , Muller‐WiefelDE , DanielK , EifeR , LeititisJ , StolpeHJ . Is S.C. erythropoietin (rhEPO) treatment thrice per week superior to an application once per week? [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 ‐ Sep 4; Jerusalem, Israel. 1992:C143. [CENTRAL: CN‐00483004] ">Amon 1992</a> found that the time to reach a Hb level greater than 11.5 g/dL were significantly longer with weekly administration (15.6 weeks) compared with thrice weekly administration (9.3 weeks). Adverse effects were uncommon and did not differ between groups and there was no deterioration in glomerular filtration rate across the two groups. However there was no significant difference in mean dose/week to sustain Hb levels between different frequencies of administration. </p> <p><a href="./references#CD011690-bbs2-0013" title="SohmiyaM , KakibaT , KatoY . Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. European Journal of Endocrinology1998;139(4):367‐70. [MEDLINE: 9820611] ">Sohmiya 1998</a> in a cross‐over study found that continuous subcutaneous infusion of epoetin beta resulted in a significantly greater increase in Hb levels compared with weekly subcutaneous injections (2.56 ± 0.77 g/dL versus 0.28 ± 0.62 g/dL, P &lt; 0.05) </p> </section> </section> <section id="CD011690-sec-0075"> <h4 class="title">Epoetin alpha administered at same frequency using different total doses</h4> <p>Three studies reported on this comparison (<a href="./references#CD011690-bbs2-0002" title="AkibaT , KoshikawaS , MimuraN , MaedaT , KRN5702 Pre‐Dialysis Study Group. Randomized double‐blind study of subcutaneous recombinant human erythropoietin in predialysis uraemic patients [abstract]. Nephrology Dialysis Transplantation1992;7(7):765. [CENTRAL: CN‐00260735] ">Akiba 1992</a>; <a href="./references#CD011690-bbs2-0004" title="FrenkenLA , VerberckmoesR , MichielsenP , KoeneRA . Efficacy and tolerance of treatment with recombinant‐human erythropoietin in chronic renal failure (pre‐dialysis) patients. Nephrology Dialysis Transplantation1989;4(9):782‐6. [MEDLINE: 2516609] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant human erythropoietin in end‐stage renal disease (predialysis) patients [abstract]. Nephrology Dialysis Transplantation1988;3(4):495. [CENTRAL: CN‐00260377] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant‐human erythropoietin in end‐state renal disease (pre‐dialysis) patients [abstract]. Kidney International1988;34(4):558. [CENTRAL: CN‐00644276] KoeneR , FrenkenL . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Nefrologia1990;10(Suppl 2):131‐6. KoeneRA , FrenkenLA . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Contributions to Nephrology1990;87:105‐12. [MEDLINE: 2093536] ">Frenken 1989</a>; <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>) </p> <section id="CD011690-sec-0076"> <h5 class="title">Epoetin alpha different doses given three times weekly</h5> <p><a href="./references#CD011690-bbs2-0004" title="FrenkenLA , VerberckmoesR , MichielsenP , KoeneRA . Efficacy and tolerance of treatment with recombinant‐human erythropoietin in chronic renal failure (pre‐dialysis) patients. Nephrology Dialysis Transplantation1989;4(9):782‐6. [MEDLINE: 2516609] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant human erythropoietin in end‐stage renal disease (predialysis) patients [abstract]. Nephrology Dialysis Transplantation1988;3(4):495. [CENTRAL: CN‐00260377] FrenkenLA , VerberckmoesR , SluiterHE , SchrijverG , MichielsenP , KoeneRA . An open study of the safety and efficacy of multiple doses of recombinant‐human erythropoietin in end‐state renal disease (pre‐dialysis) patients [abstract]. Kidney International1988;34(4):558. [CENTRAL: CN‐00644276] KoeneR , FrenkenL . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Nefrologia1990;10(Suppl 2):131‐6. KoeneRA , FrenkenLA . Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?. Contributions to Nephrology1990;87:105‐12. [MEDLINE: 2093536] ">Frenken 1989</a> reported no statistical significance in the final Hb in groups which received 100 IU/kg/dose (<a href="./references#CD011690-fig-0012" title="">Analysis 3.1</a>.1 (1 study, 16 participants): MD 0.70 g/dL, 95% CI ‐0.78 to 2.18) or 150 IU/kg/dose (<a href="./references#CD011690-fig-0012" title="">Analysis 3.1</a>.2 (1 study, 16 participants): MD 1.00 g/dL, 95% CI ‐0.18 to 2.18) compared with 50 IU/kg/dose. Final mean arterial blood pressures and serum creatinine levels did not differ between subgroups (<a href="./references#CD011690-fig-0013" title="">Analysis 3.2</a>; <a href="./references#CD011690-fig-0014" title="">Analysis 3.3</a>). No anti‐erythropoietin antibodies were detected in the study participants. The study reported overall improvement in well‐being in all participants receiving epoetin. </p> </section> <section id="CD011690-sec-0077"> <h5 class="title">Epoetin alpha different doses given every four weeks</h5> <p><a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a> reported no significant difference in the final Hb level (<a href="./references#CD011690-fig-0015" title="">Analysis 4.1</a> (1 study, 144 participants): MD 0.17 g/dL 95% CI ‐0.19 to 0.53) and the number reaching target Hb (<a href="./references#CD011690-fig-0016" title="">Analysis 4.2</a> (1 study, 144 participants): RR 1.07, 95% CI 0.92 to 1.24) when epoetin alpha was administered at 20,000 U compared with 40,000 U every four weeks. There was no significant difference in all‐cause mortality (<a href="./references#CD011690-fig-0017" title="">Analysis 4.3</a>.1), the number with hypertension (<a href="./references#CD011690-fig-0018" title="">Analysis 4.4</a>.1), thrombovascular complications (<a href="./references#CD011690-fig-0018" title="">Analysis 4.4</a>.2) or number of patients requiring transfusions (<a href="./references#CD011690-fig-0018" title="">Analysis 4.4</a>.3). </p> </section> <section id="CD011690-sec-0078"> <h5 class="title">Epoetin alpha different doses given every week</h5> <p><a href="./references#CD011690-bbs2-0002" title="AkibaT , KoshikawaS , MimuraN , MaedaT , KRN5702 Pre‐Dialysis Study Group. Randomized double‐blind study of subcutaneous recombinant human erythropoietin in predialysis uraemic patients [abstract]. Nephrology Dialysis Transplantation1992;7(7):765. [CENTRAL: CN‐00260735] ">Akiba 1992</a> reported that 6000 IU and 12,000 IU given weekly increased HCT levels more than 3000 IU/week. No standard deviations were provided. </p> </section> </section> <section id="CD011690-sec-0079"> <h4 class="title">Epoetin alpha intravenous versus subcutaneous administration</h4> <p><a href="./references#CD011690-bbs2-0001" title="AggarwalHK , KaushikG , SinghS , NandN , SinghM . Comparison of efficacy of subcutaneous versus intravenous erythropoeitin in anaemia of chronic renal failure [abstract no: 227]. Journal of the Association of Physicians of India2001;49(Jan). [CENTRAL: CN‐01094842] AggarwalHK , NandN , SinghS , SinghM , KaushikG . Comparative efficacy of subcutaneous versus intravenous dose of erythropoietin in pre‐dialysis patients of chronic renal failure. Journal of Indian Academy of Clinical Medicine2002;3(1):46‐50. [CENTRAL: CN‐00689631] ">Aggarwal 2002</a> reported no significant difference in final Hb at 12 weeks (<a href="./references#CD011690-fig-0019" title="">Analysis 5.1</a> (20 participants): MD ‐0.99 g/dL, 95% CI ‐2.08 to 0.10) between intravenous and subcutaneous administration of epoetin alpha. </p> </section> <section id="CD011690-sec-0080"> <h4 class="title">Epoetin alpha versus other epoetins or biosimilars</h4> <p>Five studies compared epoetin alpha with other epoetins or biosimilars.</p> <p><a href="./references#CD011690-bbs2-0005" title="GertzB , KesP , EssaianA , BiasP , BuchnerA , ZellnerD . Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre‐dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research &amp; Opinion2012;28(7):1101‐10. [MEDLINE: 22533679] ">Gertz 2012</a> found no significant differences in final Hb (<a href="./references#CD011690-fig-0020" title="">Analysis 6.1</a> (288 participants): MD ‐0.02 g/dL, 95% CI ‐0.25 to 0.21) and weekly epoetin doses (<a href="./references#CD011690-fig-0021" title="">Analysis 6.2</a> (288 participants) MD 0.40 U/kg, 95% CI ‐5.68 to 6.48) between epoetin theta and epoetin beta. No significant differences were noted in all‐cause mortality (<a href="./references#CD011690-fig-0022" title="">Analysis 6.3</a> (288 participants): RR 2.46, 95% CI 0.29 to 20.77), hypertension (<a href="./references#CD011690-fig-0023" title="">Analysis 6.4</a>.1 (288 participants): RR 0.35, 95% CI 0.11 to 1.08); transfusions (<a href="./references#CD011690-fig-0023" title="">Analysis 6.4</a>.2 (288 participants): RR 1.48, 95% CI 0.06 to 36.10) and discontinuation of therapy (<a href="./references#CD011690-fig-0023" title="">Analysis 6.4</a>.3 (288 participants): RR 1.77, 95% CI 0.68 to 4.63). No neutralising antibodies were noted in either intervention group. Most of the deaths were due to cardiovascular complications reflecting the population studied. </p> <p>The quality of this single study was assessed as moderate for the surrogate outcome of final Hb but as low for mean weekly epoetin dose because of imprecision (<a href="./full#CD011690-tbl-0003">summary of findings Table 3</a>). The quality of evidence for patient‐centred outcomes was assessed as low for all‐cause mortality, need for blood transfusion and discontinuation of medications and moderate for hypertension because of imprecision due to small numbers of events </p> <p><a href="./references#CD011690-bbs2-0006" title="Haag‐WeberM , EckardtKU , HorlWH , RogerSD , VetterA , RothK . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin‐alpha (HX575) in non‐dialysis patients with renal anemia: a multi‐center, randomized, double‐blind study. Clinical Nephrology2012;77(1):8‐17. [MEDLINE: 22185963] ">Haag‐Weber 2012</a> (337 participants) compared the biosimilar HX575 epoetin alpha with epoetin alpha; both medications were administered subcutaneously. The study was ceased when two patients receiving HX575 developed antibodies to epoetin and pure red cell aplasia and HX575 epoetin alpha was withdrawn for subcutaneous administration. The change in Hb from baseline at 13 weeks did not differ between groups (HX575 2.2 ± 0.9 g/dL; epoetin alpha 2.2 ± 1.0 g/dL) but the data could not be included in meta‐analyses since no denominators were provided and information could not be obtained from the authors. </p> <p><a href="./references#CD011690-bbs2-0009" title="MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP . Epoetin delta corrects and maintains haemoglobin in pre‐end stage renal disease [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:140. [CENTRAL: CN‐00461317] MignonF , AndrassyK , EsnaultVL , KuhlmannMK , SinnassamyP , European HMR4396 Study Group. Novel human erythropoietin corrects and maintains hemoglobin in pre‐end stage renal disease (ESRD) when administered twice weekly subcutaneously [abstract no: A0384]. Journal of the American Society of Nephrology2000;11(Sept):71A. [MEDLINE: CN‐00794723] PrattRD . Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis [abstract no: TH‐PO377]. Journal of the American Society of Nephrology2006;17(Abstracts):187A. [CENTRAL: CN‐00765050] ">Mignon 2000</a> (65 participants) found no significant differences in response between epoetin delta and epoetin alpha when both were given at the same dose (50 IU/kg/wk). Adverse events were similar between epoetin delta and epoetin alpha. No data were available from <a href="./references#CD011690-bbs2-0007" title="KnebelW , PalmenM , DowellJA , GastonguayM . Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. Journal of Clinical Pharmacology2008;48(7):837‐48. [MEDLINE: 18490498] ">Knebel 2008</a> (60 participants). Since epoetin delta production was ceased for commercial reasons and no information could be obtained from the pharmaceutical company, no meta‐analyses were performed. </p> <p><a href="./references#CD011690-bbs2-0008" title="KronborgJ , WillassenY , StromsaetherCE , PaulsenD . Pain after subcutaneous injection of erythropoietin (EPO). A comparison of two different preparations [abstract]. Journal of the American Society of Nephrology1994;5(3):460. ">Kronborg 1994</a> (29 participants) found that pain scores were higher in participants treated with subcutaneous epoetin alpha compared with epoetin beta. The results were provided as median with inter‐quartile ranges so could not be included in a meta‐analysis. </p> </section> <section id="CD011690-sec-0081"> <h4 class="title">Other outcomes</h4> <p>From the available studies, we were not able to analyse the outcomes of causes of death, cardiovascular and cerebrovascular morbidity, kidney function, number of hospitalisations, additional requirement for IV iron, serious infections, or de novo malignancies. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011690-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011690-sec-0082">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011690-sec-0119">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011690-sec-0082"></div> <section id="CD011690-sec-0083"> <h3 class="title" id="CD011690-sec-0083">Summary of main results</h3> <p>Fourteen studies (30 reports) with 2616 participants were included in this review, which evaluated the efficacy and safety of short‐acting ESAs in CKD patients, not requiring dialysis. </p> <p>Six studies (1613 enrolled participants) compared epoetin alpha or epoetin beta at different frequencies using the same total dose in each group, with two studies having insufficient data for inclusion in meta‐analyses. Among four studies, no significant differences in end of study Hb, in the number of participants achieving target Hb, in all‐cause mortality or in adverse effects were identified when dosing every two weeks was compared with weekly dosing or when four weekly dosing was compared with two weekly dosing. These data suggest that larger doses of short‐acting epoetins given less frequently can be administered to CKD patients not requiring dialysis without a loss of efficacy or an increase in adverse effects. However this conclusion is based on low quality evidence (<a href="./full#CD011690-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011690-tbl-0002">summary of findings Table 2</a>). Three studies (including <a href="./references#CD011690-bbs2-0014" title="McGowanT , BeaverJS , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of epoetin alfa (EPO) in anemic subjects with chronic kidney disease [abstract no: SU‐PO787]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00765903] McGowanT , TangL , WolfsonM . Analysis of hemoglobin decline following hemoglobin increase to &gt;12 g/dL when initiating epoetin alfa using extended dosing regimens [abstract no: SU‐PO786]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):758A. [CENTRAL: CN‐00763607] McGowanT , VaccaroNM , BeaverJS , MassarellaJ , WolfsonM . Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1006‐14. [MEDLINE: 18417741] SpinowitzB , GermainM , BenzR , WolfsonM , McGowanT , TangKL , et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN2008;3(4):1015‐21. [MEDLINE: 18400964] WolfsonM , SpinowitzB , GermainM , BenzR , EpoetinAEDSG . Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease [abstract no: 238]. American Journal of Kidney Diseases2007;49(4):B84. [CENTRAL: CN‐00644242] ">Spinowitz 2008</a>, in which different frequencies were also evaluated) compared different total doses of epoetin alpha given at the same frequency though data from only two studies could be included in meta‐analyses. Both studies found no significant difference in final Hb or adverse effects with different total doses. </p> <p>The remaining five studies evaluated different interventions. One study (288 participants) compared epoetin theta with epoetin alpha and found no significant differences in efficacy or adverse effects. Two studies (125 participants) compared epoetin delta with epoetin alpha. However no results were available since the pharmaceutical company withdrew epoetin delta for commercial reasons. The fourth study was terminated before completion after two patients receiving the biosimilar epoetin, HX575 epoetin alpha, developed anti‐epoetin antibodies and pure red cell aplasia. The fifth study found significantly higher pain scores with subcutaneous epoetin alpha compared with epoetin beta. </p> </section> <section id="CD011690-sec-0084"> <h3 class="title" id="CD011690-sec-0084">Overall completeness and applicability of evidence</h3> <p>For this review we were only able to identify 14 studies (2616 participants), which evaluated different frequencies, doses or routes of administration of the same epoetins or compared different epoetins in pre‐dialysis patients. Only seven studies contributed data to meta‐analyses with two of these studies enrolling only 20 and 24 patients respectively. Two studies evaluated children and neither had sufficient data for inclusion in meta‐analyses. Two studies were terminated before completion without available data when the pharmaceutical company ceased production of epoetin delta for commercial reasons. One study was terminated when two patients developed antibody mediated pure red cell aplasia with HX575 epoetin alpha, a biosimilar epoetin. No studies in pre‐dialysis patients were identified, which evaluated HX575 epoetin alpha, given intravenously, or of SB309 (epoetin zeta) given intravenously or subcutaneously. These biosimilar epoetins are approved for use by the European Medicines Agency. Preliminary information indicates that SB309 (epoetin zeta, Epoetin Hospira<sup>®</sup>) has not been approved for use in the USA (<a href="./references#CD011690-bbs2-0036" title="FDA rejects Hospira's Epoetin Biosimilar. www.bigmoleculewatch.com/2015/10/27/fda‐rejects‐hospiras‐epogen‐biosimilar/2015. ">Big Molecule Watch Blog 2015</a>). </p> <p>Patient‐centred outcomes were generally poorly reported. Only one study reported on a quality of life assessment with no differences identified in end of study quality of life scores between different frequencies of epoetin alpha administration (<a href="./references#CD011690-bbs2-0012" title="ProvenzanoR , BhaduriS , SinghAK , PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clinical Nephrology2005;64(2):113‐23. [MEDLINE: 16114787] ProvenzanoR , BhaduriS , TangKL , KlausnerM , SinghA . Prospective, randomized evaluation of extended epoetin alfa dosing for treatment of anemia of chronic kidney disease (CKD): PROMPT interim analysis. [abstract no: SA‐PO729]. Journal of the American Society of Nephrology2003;14(Nov):457A‐8A. [CENTRAL: CN‐00550618] ProvenzanoR , BhaduriS , TangL , KlausnerM , SinghAK . Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: final results from the PROMPT Study. [abstract no: SU‐PO055]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00583874] ProvenzanoR , SinghAK . Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocrine Practice2007;13(3):251‐9. [MEDLINE: 17599856] ">PROMPT Study 2005</a>). Six studies reported on all‐cause mortality. Data on hypertension and thrombovascular events, adverse effects known to be associated with epoetin administration, could be included in meta‐analyses from only five studies. Data from four studies on the number of participants, requiring blood transfusions, could be included in meta‐analyses. Anti‐erythropoietin antibodies, which can cause pure red cell aplasia, were assessed In only five studies. </p> </section> <section id="CD011690-sec-0085"> <h3 class="title" id="CD011690-sec-0085">Quality of the evidence</h3> <p>Of the fourteen studies included in this review, four studies were available in abstract format only. </p> <p>Only three of 14 studies demonstrated adequate random sequence generation, with only two studies assessed as showing low risk of bias for allocation concealment. Blinding of participants and personnel was at low risk of bias in one study only. Blinding of outcome assessment was judged at low risk in 13 studies as the outcome measures were laboratory based. Attrition and reporting bias were at low risk of bias in eight and seven studies respectively (<a href="#CD011690-fig-0003">Figure 3</a>). </p> <p>Only five of 14 studies could be included in the Summary of Findings tables as other comparisons included single small studies only or data which could not be included in the meta‐analyses. Overall the quality of the studies (<a href="./references#CD011690-bbs2-0046" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE Guidelines:1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [MEDLINE: 21195583] ">GRADE 2011a</a>; <a href="./references#CD011690-bbs2-0047" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE Guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. [MEDLINE: 21208779] ">GRADE 2011b</a>) included in meta‐analyses was assessed as low indicating that our confidence in the results is significantly reduced because of poor study quality and the use of surrogate outcomes as the primary outcomes of the included studies. </p> <p>The quality of the studies included in meta‐analyses comparing epoetin alpha every two weeks with weekly administration (<a href="./full#CD011690-tbl-0001">summary of findings Table for the main comparison</a>) and in meta‐analyses comparing epoetin alpha every four weeks with two weekly administration (<a href="./full#CD011690-tbl-0002">summary of findings Table 2</a>) for the efficacy outcomes of change in Hb level and number reaching target Hb were assessed as low or very low. These were down‐graded for indirectness on the GRADE profile, since these were surrogate outcomes and not patient‐centred outcomes. In the comparison of epoetin alpha given every four weeks compared with every two weeks, the results were further downgraded because of marked unexplained heterogeneity. In addition the quality of the evidence for efficacy was downgraded because of poor study design and/or reporting particularly of sequence generation and allocation concealment and for imprecision, where small numbers of events resulted in wide confidence intervals. Outcomes for adverse effects were downgraded because of poor study design and imprecision. </p> <p>The quality of the single study included in meta‐analyses comparing epoetin theta with epoetin beta was assessed as moderate for the surrogate outcome of final Hb but as low for mean weekly epoetin dose because of imprecision (<a href="./full#CD011690-tbl-0003">summary of findings Table 3</a>). The quality of evidence for patient‐centred outcomes was assessed as low for all‐cause mortality, need for blood transfusion and discontinuation of medications and moderate for hypertension because of imprecision due to small numbers of events. </p> </section> <section id="CD011690-sec-0086"> <h3 class="title" id="CD011690-sec-0086">Potential biases in the review process</h3> <p>For this review a comprehensive search of the Cochrane Kidney and Transplant's Specialised Register was performed, which reduced the likelihood that eligible published studies were omitted from the review. Eligible studies published after the last search date of 12 September 2016 or published in congress proceedings not routinely searched could have been missed. Four studies were only available in abstract form which provided limited information on study methods and results. Inclusion of these studies could be a source of bias. </p> <p>The review was completed independently by at least three authors, who participated in all steps of the review. This limited the risk of errors in determining study eligibility, data extraction, risk of bias assessment and data synthesis. </p> <p>Many of the earlier epoetin alpha studies were small with incomplete information on study methods and results. Further information could not be obtained about these studies from investigators or the literature. </p> <p>Although six of the included studies were sponsored by pharmaceutical companies, these were multi‐centre studies and so were able to attract larger patient numbers. In two of these studies per‐protocol data were included in meta‐analyses for the primary outcomes of final Hb or change in Hb, since ITT data were only presented graphically. In both studies the authors reported that sensitivity analyses using ITT populations were consistent with those from the per‐protocol populations, thus increasing confidence in the findings. </p> </section> <section id="CD011690-sec-0087"> <h3 class="title" id="CD011690-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>No evidence was identified by the KDIGO working group to suggest that any given type of ESA was superior to another in terms of efficacy and safety (<a href="./references#CD011690-bbs2-0052" title="KDIGO . KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International ‐ Supplement2012;2(4):279‐335. ">KDIGO 2012</a>). The Working Group suggested ESA choice was dependent on patient and country specific issues including availability, cost and treatment setting. The NICE guidelines 2015 (<a href="./references#CD011690-bbs2-0060" title="NICEGuideline . Chronic kidney disease: managing anaemia. Published: 3 June 2015. www.nice.org.uk/guidance/ng8 (accessed 15 December 2016). ">NICE 2015</a>) suggest the choice of ESA should be discussed with the patient with anaemia and CKD when initiating the patient on treatment, taking into consideration the route of administration and the local availability of ESA. There is no evidence to distinguish between ESAs in term of efficacy. The findings of this systematic review confirm these recommendations. </p> <p>The findings of this review complement other Cochrane Kidney and Transplant reviews of ESA including an updated review comparing epoetin in pre‐dialysis patients with placebo or no specific treatment (<a href="./references#CD011690-bbs2-0040" title="CodyJD , HodsonEM . Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. Cochrane Database of Systematic Reviews2016, Issue 1. [DOI: 10.1002/14651858.CD003266.pub3] ">Cody 2016</a>), a review evaluating the benefits and harms of different Hb or HCT targets in CKD patients receiving ESA treatment for anaemia (<a href="./references#CD011690-bbs2-0073" title="StrippoliGF , NavaneethanSD , CraigJC , PalmerSC . Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD003967.pub2] ">Strippoli 2006</a>), a review evaluating darbepoetin (<a href="./references#CD011690-bbs2-0064" title="PalmerSC , SaglimbeneV , CraigJC , NavaneethanSD , StrippolliGF . Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD009297.pub2] ">Palmer 2014b</a>) and a network meta‐analysis of studies of any ESA formulation (<a href="./references#CD011690-bbs2-0063" title="PalmerSC , SaglimbeneV , MavridisD , SalantiG , CraigJC , TonelliM , et al. Erythropoiesis‐stimulating agents for anaemia in adults with chronic kidney disease: a network meta‐analysis. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD010590.pub2] ">Palmer 2014a</a>). While ESAs clearly reduce the need for blood transfusion, no systematic review to date has found clear evidence for the superiority of any ESA formulation over any other formulation based on available efficacy and safety data. </p> <p>For consumers, clinicians and funders, considerations such as drug cost, availability and preferences for dosing frequency should be considered as the basis for individualising anaemia care due to lack of data for comparative differences in the clinical benefits and harms of different ESA preparations. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011690-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011690-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011690-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011690-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 1 Change in haemoglobin level." data-id="CD011690-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 1 Change in haemoglobin level. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 2 Number reaching target haemoglobin." data-id="CD011690-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 2 Number reaching target haemoglobin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 3 Number of deaths." data-id="CD011690-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 3 Number of deaths.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 4 Adverse events." data-id="CD011690-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 4 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 1 Change in haemoglobin level." data-id="CD011690-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 1 Change in haemoglobin level. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 2 Number reaching target haemoglobin." data-id="CD011690-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 2 Number reaching target haemoglobin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 3 Number of deaths." data-id="CD011690-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 3 Number of deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 4 Adverse events." data-id="CD011690-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 4 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Epoetin alpha different doses given three times weekly, Outcome 1 Final haemoglobin." data-id="CD011690-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Epoetin alpha different doses given three times weekly, Outcome 1 Final haemoglobin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Epoetin alpha different doses given three times weekly, Outcome 2 Mean arterial BP." data-id="CD011690-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Epoetin alpha different doses given three times weekly, Outcome 2 Mean arterial BP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Epoetin alpha different doses given three times weekly, Outcome 3 Final creatinine levels." data-id="CD011690-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Epoetin alpha different doses given three times weekly, Outcome 3 Final creatinine levels. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 1 Final haemoglobin." data-id="CD011690-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 1 Final haemoglobin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 2 Number reaching target haemoglobin." data-id="CD011690-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 2 Number reaching target haemoglobin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 3 Number of deaths." data-id="CD011690-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 3 Number of deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 4 Adverse events." data-id="CD011690-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 4 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Epoetin alpha IV versus subcutaneous administration, Outcome 1 Final haemoglobin." data-id="CD011690-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Epoetin alpha IV versus subcutaneous administration, Outcome 1 Final haemoglobin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Epoetin theta versus epoetin beta, Outcome 1 Final Hb." data-id="CD011690-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Epoetin theta versus epoetin beta, Outcome 1 Final Hb.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Epoetin theta versus epoetin beta, Outcome 2 Mean weekly epoetin dose." data-id="CD011690-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Epoetin theta versus epoetin beta, Outcome 2 Mean weekly epoetin dose.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Epoetin theta versus epoetin beta, Outcome 3 Deaths." data-id="CD011690-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Epoetin theta versus epoetin beta, Outcome 3 Deaths.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011690-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/urn:x-wiley:14651858:media:CD011690:CD011690-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_t/tCD011690-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Epoetin theta versus epoetin beta, Outcome 4 Adverse events." data-id="CD011690-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Epoetin theta versus epoetin beta, Outcome 4 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/media/CDSR/CD011690/image_n/nCD011690-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011690-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Epoetin alpha every 2 weeks versus to weekly for anaemia in CKD patients not receiving dialysis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Epoetin alpha every 2 weeks versus to weekly for anaemia in CKD patients not receiving dialysis </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> anaemia in predialysis patients<br/> <b>Intervention:</b> epoetin alpha every 2 weeks<br/> <b>Comparison:</b> weekly </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with weekly</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Epoetin alpha every 2 weeks</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in Hb level</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Hb level was 0 g/dL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Hb level in the intervention group was 0.19 g/dL lower (0.32 g/dL lower to 0.06 g/dL lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>798 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>downgraded for study limitations and indirectness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Number reaching target Hb</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.96<br/> (0.93 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>798 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations and indirectness</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>960 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>922 per 1000<br/> (893 to 951) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>947 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>910 per 1000<br/> (881 to 938) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Number of deaths</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.89<br/> (0.38 to 2.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>838 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations and imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/> (10 to 57) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (9 to 46) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: RBC transfusions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.56<br/> (0.71 to 3.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>580 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for imprecision and study limitations</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000<br/> (23 to 114) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/> (26 to 128) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: hypertension</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.85<br/> (0.55 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>838 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000<br/> (55 to 132) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/> (52 to 126) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: thrombovascular events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.41<br/> (0.67 to 3.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>838 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations and imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/> (18 to 83) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/> (18 to 80) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; <b>Hb:</b> haemoglobin; <b>RBC:</b> red blood cells </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> allocation concealment unclear in 3 of 4 studies </p> <p><sup>2</sup> surrogate outcome </p> <p><sup>3</sup> few studies with low numbers and wide confidence </p> <p><sup>4</sup> allocation concealment unclear in 2 of 3 studies </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Epoetin alpha every 2 weeks versus to weekly for anaemia in CKD patients not receiving dialysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011690-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Epoetin alfa every four weeks versus with every two weeks in CKD patients not receiving dialysis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Epoetin alfa every four weeks versus with every two weeks in CKD patients not receiving dialysis </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> anaemia in predialysis patients<br/> <b>Intervention:</b> epoetin alpha every 4 weeks<br/> <b>Comparison:</b> every 2 weeks </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with every 2 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Epoetin alpha every 4 weeks</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in Hb level</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Hb level was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in Hb level in the intervention group was 0.15g/dL lower (0.41 g/dL lower to 0.1g/dL more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>671 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>downgraded for study limitations, heterogeneity and indirectness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Number reaching target Hb</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.95<br/> (0.84 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>687 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations, heterogeneity and indirectness</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>916 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>870 per 1000<br/> (769 to 980) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>895 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>850 per 1000<br/> (752 to 957) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Number of deaths</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.95<br/> (0.33 to 2.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>724 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations, imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (7 to 62) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (9 to 72) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: RBC transfusions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.26<br/> (0.53 to 2.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>470 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations, imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/> (20 to 114) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000<br/> (18 to 103) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: hypertension</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.02<br/> (0.62 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>724 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000<br/> (44 to 119) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000<br/> (38 to 104) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: arteriovenous complications</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.02<br/> (0.39 to 2.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>724 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for study limitations, imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (10 to 68) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/> (9 to 62) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; <b>Hb:</b> haemoglobin; <b>RBC:</b> red blood cells </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> two of the three studies had unclear allocation concealment </p> <p><sup>2</sup> surrogate outcome </p> <p><sup>3</sup> unexplained heterogeneity </p> <p><sup>4</sup> small numbers with wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Epoetin alfa every four weeks versus with every two weeks in CKD patients not receiving dialysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011690-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Epoetin theta versus epoetin beta in CKD patients not receiving dialysis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Epoetin theta versus epoetin beta in CKD patients not receiving dialysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> anaemia in predialysis patients<br/> <b>Intervention:</b> epoetin theta<br/> <b>Comparison:</b> epoetin beta </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with epoetin beta</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Epoetin theta</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final Hb</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final Hb was 0 g/dL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final Hb in the intervention group was 0.02 g/dL lower (0.25 g/dL lower to 0.21 g/dL higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>downgraded for indirectness ‐ surrogate outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean weekly epoetin dose</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean weekly epoetin dose was 0 units/week</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean weekly epoetin dose in the intervention group was 0.4 units per week higher (5.68 units per week lower 6.48 units/week higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>downgraded for indirectness ‐ surrogate outcomes and imprecision</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Deaths</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 2.46<br/> (0.29 to 20.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>288 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (3 to 219) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (3 to 218) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: hypertension</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.35<br/> (0.11 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>288 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (8 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (8 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: RBC transfusions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.48<br/> (0.06 to 36.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>288 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>downgraded for imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events: discontinuation of therapy</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.77<br/> (0.68 to 4.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>288 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>downgraded for imprecision</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000<br/> (36 to 244) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000<br/> (36 to 244) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; <b>RBC:</b> red blood cells </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Surrogate outcome, not a patient‐centred outcome </p> <p><sup>2</sup> Small numbers, wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Epoetin theta versus epoetin beta in CKD patients not receiving dialysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/full#CD011690-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011690-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Epoetin alpha every 2 weeks versus weekly</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in haemoglobin level <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.33, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number reaching target haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.93, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.38, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 RBC transfusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.71, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.55, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Thrombovascular events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.67, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Adverse events leading to discontinuation of therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.20, 4.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Epoetin alpha every 2 weeks versus weekly</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011690-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Epoetin alpha every 4 weeks versus every 2 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in haemoglobin level <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.43, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number reaching target haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.33, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 RBC transfusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.53, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.62, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Arteriovenous complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.39, 2.68]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Epoetin alpha every 4 weeks versus every 2 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011690-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Epoetin alpha different doses given three times weekly</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Final haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 100 U/kg versus 50 U/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 150 U/kg versus 50 U/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean arterial BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 100 IU/kg/wk versus 50 IU/kg/wk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 150 IU/kg/wk versus 50 IU/kg/wk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Final creatinine levels <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 100 IU/kg/wk versus 50 IU/kg/wk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 150 IU/kg/wk versus 50 IU/kg/wk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Epoetin alpha different doses given three times weekly</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011690-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Epoetin alpha different doses given every four weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Final haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number reaching target haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Thrombovascular events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 RBC transfusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Epoetin alpha different doses given every four weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011690-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Epoetin alpha IV versus subcutaneous administration</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Final haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Epoetin alpha IV versus subcutaneous administration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011690-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Epoetin theta versus epoetin beta</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Final Hb <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean weekly epoetin dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 RBC transfusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Discontinuation of therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Epoetin theta versus epoetin beta</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011690.pub2/references#CD011690-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011690.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011690-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011690-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011690-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD011690-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011690-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011690-note-0012">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011690\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011690\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011690\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011690\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011690\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011690.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011690.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011690.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011690.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011690.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717001096"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011690.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717001100"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011690.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dad3e5ec7f3f1',t:'MTc0MDcxNzAwMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 